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ATP  Adenosine triphosphate
CASK  Calcium/calmodulin-dependent serine protein kinase
CD2AP  CD2-associated protein
cDNA  Complementary deoxyribonucleic acid
CNF  Congenital nephrotic syndrome of the Finnish type
CNS  Central nervous system
cpm  Counts per minute, 
  a scintillation measure unit of radioactivity
CTLA-4 Cytotoxic T lymphocyte antigen-4
DAA  Densin autoantibodies
DN  Diabetic nephropathy
DTT  Dithiothreitol, a chemical reagent
E  Embryonic day
FAA  Filtrin autoantibodies
FAM  6-carboxy-fl uorescein
FAT  A member of cadherin superfamily, protocadherin
FITC  Fluorescein isothiocyanate
GAD  Glutamic acid decarboxylase
GADA  Glutamic acid decarboxylase autoantibodies
GFR  Glomerular fi ltration rate
GLUT1,-2,-4 Glucose transporter proteins
GM-CSF  granulocyte macrophage-colony stimulating factor
HLA  Human leucocyte antigen
IA-2  Islet antigen 2
IA-2A  Islet antigen 2 autoantibodies
IAA  Insulin autoantibodies
ICA  Islet cell autoantibodies
Ig  Immunoglobulin
IgG  Immunoglobulin G
IL-4  Interleukin-4
IQGAP1 IQ motif-containing GTPase-activating protein1
KIRREL Kin of irregular chiasm C-roughest
LADA  Latent autoimmune diabetes in adults
LAP  Leucine-rich repeats and PSD-95/Dlg-A/ZO-1
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MAGI  Membrane-associated guanylate kinase inverted
Min  Minute
M-MLV Moloney murine leukemia virus
MODY  Maturity-onset diabetes of the young
mRNA  Messenger ribonucleic acid
NAA  Nephrin autoantibodies
NEPH1,-2,-3 Nephrin related genes also known as KIRREL-2,-3,  
  Filtrin and NLG
NPHS1  Nephrosis 1, gene encoding nephrin
NPHS2  Nephrosis 2, gene encoding podocin
NS  non-signifi cant
o/n  Overnight
PBS  Phosphate-buffered saline
PCR  Polymerase chain reaction
PDZ  PSD-95/Dlg-A/ZO-1, an interaction domain of proteins
PP  Pancreatic polypeptide
PTPN22 Protein tyrosine phosphatase 22
rER  Rough endoplasmic reticulum
RIA  Radioimmunoprecipitation assay
RT-PCR Reverse transcriptase-polymerase chain reaction
RU  Relative units
SD  Standard deviation
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide 
  gel electrophoresis
SNP  Single nucleotide polymorphism
TBST  Tris-buffered saline with Tween-20
TNF-   Tumor necrosis factor-
TRPC6  Transient receptor potential channel 6
VIC  Fluorescein dye in Taqman Real Time PCR, 
  proprietary name
VNTR  Variable number of tandem repeats
ZO-1  Zonula occludens 1 gene
9Type 1 diabetes is a disease 
where the insulin-producing beta 
cells of the pancreas are destroyed 
by an autoimmune mechanism. 
The incidence of type 1 diabetes, 
as well as the incidence of the 
diabetic kidney complication, 
diabetic nephropathy, are 
increasing worldwide. Nephrin 
is a crucial molecule for the 
fi ltration function of the kidney. 
It localises in the podocyte foot 
processes partially forming the 
interpodocyte fi nal sieve of 
the fi ltration barrier, the slit 
diaphragm. The expression of 
nephrin is altered in diabetic 
nephropathy. Recently, nephrin 
was found from the beta cells 
of the pancreas as well, which 
makes this molecule interesting 
in the context of type 1 diabetes 
and especially in diabetic 
nephropathy. In this thesis 
work, the expression of other 
podocyte molecules in the beta 
cells of the pancreas, in addition 
to nephrin, were deciphered. 
It was also hypothesised that 
patients with type 1 diabetes 
may develop autoantibodies 
against novel beta cell molecules 
comparably to the formation of 
autoantibodies to GAD, IA-2 and 
insulin. The possible association 
ABSTRACT
of such novel autoantibodies 
with the pathogenesis of diabetic 
nephropathy was also assessed. 
Furthermore, expression of 
nephrin in lymphoid tissues has 
been suggested, and this issue 
was more thoroughly deciphered 
here.
The expression of nephrin in 
the human lymphoid tissues, and 
a set of podocyte molecules in the 
human, mouse and rat pancreas 
at the gene and protein level 
were studied by polymerase chain 
reaction (PCR) -based methods 
and immunochemical methods. 
To detect autoantibodies to 
novel beta cell molecules, specifi c 
radioimmunoprecipitation assays 
were developed. These assays 
were used to screen a follow-up 
material of 66 patients with type 
1 diabetes and a patient material 
of 150 diabetic patients with signs 
of diabetic nephropathy.
Nephrin expression was 
detected in the lymphoid follicle 
germinal centres, specifi cally 
in the follicular dendritic cells. 
In addition to the previously 
reported expression of nephrin 
in the pancreas, expression of 
the podocyte molecules, densin, 
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fi ltrin, FAT and alpha-actinin-4 
were detected in the beta cells. 
Circulating antibodies to nephrin, 
densin and fi ltrin were discovered 
in a subset of patients with type 1 
diabetes. However, no association 
of these autoantibodies with 
the pathogenesis of diabetic 
nephropathy was detected.
In conclusion, the expression 
of fi ve podocyte molecules in 
the beta cells of the pancreas 
suggests some molecular 
similarities between the two cell 
types. The novel autoantibodies 
against shared molecules of 
the kidney podocytes and the 
pancreatic beta cells appear to be 
part of the common autoimmune 
mechanism in patients with type 
1 diabetes. No data suggested 
that the autoantibodies would 
be active participants of the 
kidney injury detected in diabetic 
nephropathy.
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The molecular structure of the 
fi nal sieve of the kidney fi ltration 
apparatus, the slit diaphragm, has 
been under intensive study over 
the last decade.  The discovery 
of nephrin was paramount, 
since it appears to be the key slit 
diaphragm protein (Kestila et al. 
1998). The discovery of nephrin 
in the pancreatic beta cells 
(Palmen et al. 2001) launched 
the idea whether other podocyte 
molecules could be expressed 
in the beta cells of the pancreas 
as well. In addition to nephrin 
expression in the kidney podocytes 
and the beta cells of the pancreas, 
preliminary data have suggested 
that nephrin expression occurs in 
the lymphoid tissues, specifi cally 
in rat spleen (Ahola et al. 1999) 
and mouse thymus (Liu et al. 
2001). Furthermore, many 
1 Introduction
beta cell molecules have been 
shown to be immunogenic and 
autoantibodies against these 
molecules are detected in patients 
with type 1 diabetes (Palmer et 
al. 1983; Baekkeskov et al. 1990; 
Lan et al. 1996). 
The purpose of this thesis was 
to explore the possible expression 
of podocyte molecules in the 
pancreas and the lymphoid tissues. 
In addition, antigen-specifi c 
r a d i o i m m u n o p r e c i p i t a t i o n 
assays (RIA) were developed 
to decipher if autoantibodies 
against nephrin and other novel 
beta cell molecules are formed in 
patients with type 1 diabetes. The 
possibility whether these novel 
autoantibodies could participate 
in the development of diabetic 
nephropathy was also assessed. 
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2.1 Pancreas
2.1.1 Structure and function
The pancreas is an organ
 located in the abdominal cavity 
and it has been descriptively 
divided into a head, a body 
and a tail. The main pancreatic 
duct runs the length of the 
gland and empties into the 
upper duodenum, together 
with the duct from the liver 
and gallbladder (Figure 1). The 
exocrine and endocrine functions 
of the pancreas are carried out 
by two distinct subunits. The 
exocrine component includes 
acinar cells that secrete digestive 
enzymes (proteolytic endo- 
and exopeptidases, amylolytic 
enzymes, lipases and nucleolytic 
enzymes) and a highly branched 
ductal system of centroacinar 
and ductal cells that transport 
these digestive enzymes into the 
intestine. The intercalated duct 
cells of the ductal system secrete 
bicarbonate which neutralises 
2 Review of the literature
the acidity of the chyme coming 
from the stomach to establish 
an optimal pH for the activity of 
digestive enzymes. The exocrine 
cells make up the majority of the 
pancreas, representing 95-99% 
of the mature pancreas (Ross et 
al. 2003a). 
The endocrine pancreas 
consists of about 1 million 
islets of Langerhans comprising 
approximately 1-2% of the volume 
of the pancreas.  The Langerhans 
islets are small spheroid clusters 
of cells, distributed throughout 
the organ. They vary considerably 
in size, ranging from tens of 
cells to several thousand cells. 
The islets are richly vascularised 
by a network of fenestrated 
capillaries. The endocrine portion 
is composed of fi ve cell types, 
alpha, beta, delta, PP (pancreatic 
polypeptide) and ghrelin cells. 
Proportions of the main cell 
types of the endocrine pancreas 
and blood glucose homeostasis 
regulating hormones secreted by 
them are described in Table 1.
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Cell type
Alpha cell
Beta cell
Delta cell
PP cell
Ghrelin cell
Proportion of the 
islet in adult
~30%
~60%
5-10%
~1%
~1%
Hormones secreted
glucagon
insulin
amylin
somatostatin
pancreatic polypeptide
ghrelin
Main function
blood glucose !
blood glucose "
insulin action modulation
insulin and glucagon "
pancreatic secretion "
insulin "
Table 1. Cell types of the endocrine pancreas and proportions of them in 
human pancreatic Langerhans islet. The main functions of the secreted 
hormones are indicated (Westermark et al. 1987; Wierup et al. 2002; Cabrera 
et al. 2006).
gallbladder
common bile duct
pancreas
pancreatic duct
intestine (duodenum)
common bile duct 
opening
Figure 1. Structure of the human pancreas. Localisation of the pancreas next 
to the intestine and the gallbladder. The main pancreatic duct runs through 
the middle line of the pancreas (Modifi ed from a picture by Houghton Miffl in 
Company, www.yourdictionary.com).
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2.1.2 Development
In the mouse, at embryonic 
day (E) 9.5 dorsal and ventral 
pancreatic buds bulge out 
from the foregut endodermal 
epithelium. This is followed by 
branching morphogenesis by 
E12.5 and subsequent fusing of the 
dorsal and ventral pancreata into 
a single organ on E14. Exocrine 
pancreas differentiates from the 
ductal epithelium to acini and 
ducts during E14.5 and E15.5. 
After E14 the endocrine cells, 
scattered as single cells within 
the ductal epithelium, proliferate 
extensively and on E16 they start 
to form islet-like clusters. The 
islet of Langerhans is fully formed 
on E19 but islet maturation and 
remodelling continues until 2-
3 weeks after birth. The fi rst 
endocrine cells detected, at 
the pancreatic bud stage E9.5, 
express glucagon and pancreatic 
polypeptide. Subsequently, the 
cells divide into distinct lineages of 
alpha, beta and PP cells. At E14 the 
somatostatin expressing delta cells 
arise. Signals from the mesoderm, 
notochord and endothelial cells 
are important for the orchestrated 
development of the pancreas 
(Habener et al. 2005; Hill 2005).
2.1.3 Blood glucose control
The main role of the hormones 
secreted by the pancreatic beta 
cells is to maintain glucose 
homeostasis in the body. Insulin 
hormone is a 6-kDa polypeptide 
consisting of two chains, the A 
and B chains, which are linked by 
disulfi de bonds. The main target 
tissues of insulin are the liver, 
skeletal muscle and adipose tissue. 
Insulin stimulates the uptake of 
glucose from the circulation mainly 
through the glucose transporter 
GLUT4 and activates glucose 
storage by activating glycogen 
synthesis. In addition to glucose 
metabolism, insulin takes part in 
lipid and protein metabolism; it 
inhibits lipase activity in adipose 
cells, accelerates amino acid 
uptake into cells and inhibits 
protein catabolism. Absence of 
insulin leads to elevated blood 
glucose levels by decreased uptake 
in the target tissues. Glucagon, 
secreted by the alpha cells, has 
mainly the opposite effects to 
insulin. Glucagon secretion is 
stimulated by the reduction in 
blood glucose concentration. It 
excites the release of glucose into 
the circulation, gluconeogenesis, 
breakdown of glycogen in the 
liver, and mobilises fats from the 
adipose cells (Ross et al. 2003a).
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In rodents, there are two 
insulin genes (Lomedico et al. 
1979; Wentworth et al. 1986) 
while in man, insulin is encoded 
by a single gene INS which is 
located on the short arm of 
chromosome 11 (11p15.5) (Harper 
et al. 1981). Insulin is derived from 
a large single-chain precursor, 
preproinsulin, which includes a 
signal peptide, the A and B chains 
and a third chain that connects 
(C-peptide) the A and B chains. 
Preproinsulin is synthesised in 
the rough endoplasmic reticulum 
(rER) and is further processed in 
the Golgi apparatus. The signal 
sequence is removed in the 
rER forming proinsulin which 
is subsequently transferred to 
Golgi apparatus. In the Golgi 
the proinsulin is enclosed in a 
clathrin-coated secretory vesicles 
and C-peptide is removed from 
the linked insulin A and B chains. 
The vesicles lose their clathrin coat 
and mature intracellular granules 
containing insulin form. When 
glucose enters the beta cell through 
glucose transporter 2 (GLUT-2), 
it increases glucose metabolism. 
The elevation in the adenosine 
triphosphate (ATP) concentration 
closes the KATP channels causing 
depolarisation of the plasma 
membrane, activation of Ca2+ 
channels, Ca2+ entry and fusion 
of the secretory vesicles with the 
plasma membrane. Finally, insulin 
is carried via efferent capillaries 
to systemic circulation (Koster et 
al. 2005).
2.2 Kidney
The kidneys are paired bean-
shaped organs located on both 
sides of the spine in the posterior 
abdominal cavity. The human 
kidney is approximately 10 cm 
long and 6.5 cm wide. The main 
function of the kidneys is the 
fi ltration of blood plasma and 
excretion of metabolic waste 
products into the urine. In addition, 
the kidneys maintain the water, 
electrolyte and pH balance of the 
body and secrete hormones which 
regulate blood pressure and red 
blood cell formation. Each kidney 
contains approximately 500 000-1 
million nephrons, the functional 
units of the kidney. Each nephron 
is composed of a compact tuft 
of capillary loops (glomerulus) 
surrounded by the Bowman’s 
capsule and an associated tubulus 
with a distinct proximal and distal 
part. The glomerulus is responsible 
for the formation of the primary 
urine and the tubular system 
reabsorbs valuable substances, 
such as water, important proteins 
and glucose, back into the 
circulation. The fi nal urine then 
fl ows from the tubules through 
the collecting duct to the renal 
pelvis and fi nally to the urinary 
bladder (Kierszenbaum 2002a).
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2.2.1 Glomerulus, podocyte and 
slit diaphragm
The glomerulus is composed 
of mesangial cells which provide 
structural support for the 
glomerular capillaries and which 
produce the mesangial matrix, 
the Bowman’s capsule where 
the primary urine is sieved and 
the three-layered glomerular 
fi ltration barrier through which 
the primary urine is formed. 
The fi ltration has been shown 
to be selective for charge and 
size (Brenner et al. 1978). The 
layers of the fi ltration barrier 
include fenestrated endothelium, 
glomerular basement membrane 
and podocytes, the highly 
specialised visceral epithelial 
cells. The podocytes are polarised 
octopus-like cells with long primary 
processes and small secondary foot 
processes.  The interdigitating 
foot processes from neighbouring 
podocytes completely surrounds 
the glomerular capillaries and a 
zipper-like intercellular junction 
structure, a slit diaphragm, 
separates the foot processes 
from each other (Rodewald et 
al. 1974). The slit diaphragm is 
the fi nal sieve of the glomerulus 
allowing passage of small 
molecules but preventing leakage 
of large molecules to urine. The 
molecular composition of the 
slit diaphragm was unknown for 
a long time, but during the last 
two decades the molecules have 
been partly characterised. The 
currently known molecules of 
the slit diaphragm area are listed 
in Table 2. The slit diaphragm 
has molecular and structural 
characteristics of tight junctions 
(Schnabel et al. 1990; Harhaj et 
al. 2004) and adherens junctions 
(Reiser et al. 2000; Inoue et al. 
2001; Ciani et al. 2003; Lehtonen 
et al. 2005), and therefore the slit 
diaphragm can be defi ned as a 
modifi ed adherens junction.
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Molecule
ZO-1
Synaptopodin
Nephrin
CD2AP
P-cadherin
Catenins
Podocin
Alpha-actinin-4
FAT
NEPH1
NEPH2
Filtrin
Densin
Fyn
CASK
MAGI-2
IQGAP1
Spectrins
TRPC6
MAGI-1
Nck
 Reference
 (Schnabel et al. 1990)
 (Mundel et al. 1997)
 (Kestila et al. 1998)
 (Shih et al. 1999)
 (Reiser et al. 2000)
 (Reiser et al. 2000)
 (Boute et al. 2000)
 (Kaplan et al. 2000)
 (Inoue et al. 2001)
 (Donoviel et al. 2001)
 (Sellin et al. 2003)
 (Ihalmo et al. 2003)
 (Ahola et al. 2003)
 (Verma et al. 2003)
 (Lehtonen et al. 2004)
 (Lehtonen et al. 2005)
 (Lehtonen et al. 2005)
 (Lehtonen et al. 2005)
 (Reiser et al. 2005)
 (Hirabayashi et al. 2005)
 (Jones et al. 2006)
Table 2. The slit diaphragm molecules arranged by the timing of their discovery 
in the podocytes. CASK, calcium/calmodulin-dependent serine protein 
kinase; CD2AP, CD2-associated protein; IQGAP1, IQ motif-containing GTPase-
activating protein1; MAGI, membrane-associated guanylate kinase inverted; 
TRPC6, canonical transient receptor potential 6; ZO-1, zonula occludens-1.
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2.2.2 Nephrin
In the interpodocyte slit 
diaphragm, nephrin was the fi rst 
molecule shown to be essential 
for the proper structure and 
function of the fi ltration slit. 
The gene encoding nephrin, 
NPHS1, was found by positional 
cloning by Kestilä and colleagues 
when they searched for the 
gene defective in patients with 
congenital nephrotic syndrome 
of the Finnish type (CNF) (Kestila 
et al. 1998). CNF is a serious 
monogenic disease manifesting 
with severe proteinuria already 
in utero and subsequent kidney 
failure due to podocyte injury. 
The NPHS1 gene is located in 
the chromosome locus 19q13.1 
(Kestila et al. 1994; Mannikko et 
al. 1995). Nephrin protein consists 
of one fi bronectin-like domain, 
eight immunoglobulin (Ig)-like 
domains, a transmembrane section 
and a short intracellular domain. 
It has been included into the 
immunoglobulin superfamily on 
the basis of its immunoglobulin-
like domains (Kestila et al. 1998). It 
was originally postulated that the 
expression of nephrin is restricted 
to the kidney glomerulus, but 
now its expression has been 
shown in the pancreas (Palmen et 
al. 2001; Zanone et al. 2005), the 
brain (Putaala et al. 2001) and the 
testis (Liu et al. 2001). In addition, 
nephrin expression has been 
suggested to occur in the placenta 
(Beall et al. 2005), the spleen 
(Ahola et al. 1999) and the thymus 
(Liu et al. 2001). The calculated 
molecular weight of nephrin is 
~135 kDa (Kestila et al. 1998) but it 
presents with a molecular weight 
of 165-185 kDa in different tissues 
(Ahola et al. 1999; Holzman et al. 
1999; Palmen et al. 2001). The 
variance in molecular weight 
has been suggested to be due 
to differential glycosylation (Yan 
et al. 2002). There appears to be 
tissue-specifi c differences in the 
regulation of nephrin expression 
(Moeller et al. 2000; Wong et al. 
2000; Eremina et al. 2002; Moeller 
et al. 2002; Beltcheva et al. 2003). 
The functions of nephrin in these 
extrarenal tissues remain poorly 
defi ned.
In the kidney, nephrin is an 
essential structural component 
of the slit diaphragm zipper-like 
cell-cell contact and it has been 
suggested that nephrin forms 
this interpodocyte bridge by a 
homotypic interaction (Kestila 
et al. 1998; Ruotsalainen et al. 
1999; Tryggvason et al. 1999). 
Furthermore, the extracellular 
parts of nephrin have been 
shown to form a heterodimeric 
interaction with the members of 
the NEPH-protein family (Barletta 
et al. 2003; Gerke et al. 2005). 
Nephrin has been suggested to be 
linked to the actin cytoskeleton 
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through adaptor molecules, 
including the CD2-associated 
protein (CD2AP) (Yuan et al. 2002) 
and Nck (Jones et al. 2006; Verma 
et al. 2006). In addition to the 
central role in the zipper-like cell-
cell contact, nephrin is essential 
for the proper cytoskeletal 
organisation of the podocytes. 
This is evident in CNF children 
lacking nephrin who present with 
fused (effaced) foot processes and 
absent slit diaphragms (Huttunen 
et al. 1980; Suren et al. 1993). 
A similar phenotype is seen in 
nephrin knock-out animal kidneys 
(Putaala et al. 2001; Rantanen et 
al. 2002).
Typically members of the 
immunoglobulin superfamily 
are involved in cell adhesion 
and signaling (Juliano 2002). 
The cytoplasmic tail of nephrin 
contains several tyrosine residues 
and thus has the ability to be 
phosphorylated (Simons et al. 
2001). Indeed, many studies 
recently have shown the 
important role of nephrin in 
initiating the outside-in signaling 
in podocytes (Huber et al. 2001; 
Simons et al. 2001; Huber et al. 
2003a; Lahdenpera et al. 2003; 
Verma et al. 2003; Li et al. 2004; 
Verma et al. 2006). The other 
established molecules of the slit 
diaphragm, podocin (Huber et 
al. 2001) and NEPH1 (Huber et al. 
2003b), have also been implicated 
in signaling processes.  Nephrin 
and NEPH1 mediated signaling 
appears to be needed for the 
proper organisation of the slit 
diaphragm cell junction and 
prevention of apoptosis of the 
podocytes (Huber et al. 2005).
2.2.3 Densin
Densin is a protein originally 
thought to be brain-specifi c, but 
recently Ahola and colleagues 
demonstrated that densin is 
found in the kidney glomerular 
podocytes where it localises in 
the slit diaphragm and appears 
to interact with nephrin (Ahola 
et al. 2003). In the brain, densin 
is an abundant protein found 
in postsynaptic densities of 
neurons where it is detected 
with the molecular weight of 
180 kDa (Apperson et al. 1996; 
Walikonis et al. 2001). However, 
in kidney glomerulus lysates 
densin appeared as a 210 kDa 
band which suggests different 
post-translational modifi cation or 
alternative splicing (Strack et al. 
2000; Ahola et al. 2003; Wang et 
al. 2003). 
Densin belongs to the LAP 
(leucine-rich repeats [LRR] and 
PDZ [PSD-95/Dlg/ZO-1] domains) 
protein family. More specifi cally 
the sequence of densin contains 
17 leucine-rich repeats, a putative 
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transmembrane domain and a 
PDZ domain. This arrangement of 
domains is similar to several cell 
adhesion molecules (Apperson 
et al. 1996; Walikonis et al. 
2001). However, the argument 
that densin is a transmembrane 
protein has been questioned 
lately since densin is not accessible 
to biotinylation, a method used 
to label extracellular parts of 
membrane proteins (Izawa et al. 
2002; Quitsch et al. 2005). In the 
light of the recent fi ndings, densin 
seems to be targeted to the inner 
leafl et of the plasma membrane 
by the leucine-rich region and to 
anchor there, but not to traverse 
the plasma membrane (Quitsch 
et al. 2005). In addition to cell-
cell contacts, other proposed 
functions of densin include signal 
transduction (Quitsch et al. 2005) 
and maintaining cell polarity 
(Bilder et al. 2000). In podocytes 
it has been suggested that densin 
could have a role in maintaining 
the apical-basal polarity (Ahola 
et al. 2003). Interestingly, a 
recent report shows that densin 
is expressed in the Sertoli cells of 
the testis and the authors suggest 
that densin could be an adherens 
junction protein between Sertoli 
cells and developing germ cells 
(Lassila et al 2006).
2.2.4 Filtrin
Filtrin/NEPH3/KIRREL2 is a 
NEPH-protein family member 
which is expressed in the beta 
cells of the pancreas (Sun et al. 
2003) and in the slit diaphragm 
(Ihalmo et al. Unpublished results) 
between the kidney glomerular 
podocytes (Ihalmo et al. 2003). 
Generally, the tissue distribution 
of fi ltrin appears to be quite 
restricted since in northern dot 
blot analysis comprising 76 human 
tissues, expression was detected 
only in the pancreas, kidney and 
lymph nodes (Ihalmo et al. 2003; 
Sun et al. 2003). In addition, 
fi ltrin appears to be expressed 
in the central nervous system 
(CNS) as well, since a fi ltrin EST 
clone has been found in a brain 
expression library (Sun et al. 2003) 
and, recently, fi ltrin was shown to 
be expressed in the developing 
CNS (Minaki et al. 2005). At 
least four splicing variants have 
been suggested for fi ltrin and 
they appear to have different 
tissue distribution. Two of them 
were found from pancreatic 
complementary DNA (cDNA), one 
from fetal brain and one from a 
retinoblastoma cell line (Sun et al. 
2003).
21
Filtrin has signifi cant sequence 
homology and structural 
similarity with several proteins 
including the other two NEPH-
family members NEPH1, NEPH2, 
mammalian KIRREL (kin of 
irregular chiasm C-roughest) and 
nephrin (Ihalmo et al. 2003; Sellin 
et al. 2003; Sun et al. 2003; Gerke 
et al. 2005). Filtrin contains fi ve 
immunoglobulin domains, one 
transmembrane domain and an 
intracellular domain (Ihalmo et 
al. 2003) and, as a member of the 
immunoglobulin superfamily, it 
has properties of cell adhesion 
molecules (Minaki et al. 2005). 
The extracellular parts of NEPH1 
(Barletta et al. 2003) and NEPH2 
(Gerke et al. 2005) interact with 
nephrin, and, in addition, all 
the NEPH family members have 
been reported to interact with 
podocin with their intracellular 
sections (Sellin et al. 2003). Filtrin 
homologues NEPH1 and NEPH2 
have been shown to have a 
signaling function (Sellin et al. 
2003). Filtrin has been proposed to 
have comparable function, since 
it has a potential phosphorylation 
site in its cytoplasmic domain 
(Ihalmo et al. 2003) and has high 
homology and structural similarity 
with NEPH1 and NEPH2. Filtrin/
NEPH3/KIRREL2 is located in the 
human genome in chromosome 
19q13.1 next to the nephrin 
(NPHS1) gene and interestingly, 
they are transcribed in opposite 
directions (Ihalmo et al. 2003). 
The functional peculiarities of 
this bidirectional promoter and 
regulatory area have not yet been 
characterised. 
2.2.5 Other slit diaphragm-
associated proteins
Nephrin and the proteins in 
its vicinity form an important 
functional complex linking the slit 
diaphragm, a cell junction, to the 
actin cytoskeleton. Indeed, the 
actin cytoskeleton of the podocyte 
foot processes is directly linked 
to the slit diaphragm protein 
complex (Huber et al. 2005). The 
adaptor molecules CD2AP (Welsch 
et al. 2001; Palmen et al. 2002) and 
ZO-1 (Huber et al. 2003b) mediate 
a direct or indirect connection 
between nephrin and the NEPH-
family members to the actin 
cytoskeleton. Nephrin has also 
been suggested to form a complex 
with adherens junction proteins P-
cadherin and p120 catenin which 
are linked to the cytoskeleton 
via the adaptor proteins ZO-1 
and CD2AP as well (Lehtonen 
et al. 2004). In addition, densin 
binds to alpha-actinin-4, the actin 
bundling protein, suggesting 
another connection between 
slit diaphragm protein complex 
and actin network (Walikonis et 
al. 2001). The large (~500 kDa) 
protocadherin FAT, also located
22
in the slit diaphragm, has been 
suggested to have a role in cell 
adhesion, signaling (Ciani et al. 
2003) and actin dynamics in the 
podocytes (Moeller et al. 2004). 
A schematic presentation of the 
proteins in the slit diaphragm 
area is shown in Figure 2.
Interference of the slit 
diaphragm protein complex has 
been shown to result in disruption 
of the podocyte architecture, 
effacement of the podocyte 
foot processes and proteinuria. 
Mutations in the podocin gene 
(NPHS2) in humans causes 
autosomal recessive steroid-
resistant nephrotic syndrome 
which rapidly proceeds to end-
stage renal disease (Boute et al. 
2000), and mutations in alpha-
actinin-4 gene (ACTN4) result 
in familial focal segmental 
glomerulosclerosis (Kaplan et 
al. 2000). Furthermore, in mice, 
Neph1 knock-out (Donoviel et al. 
2001) caused proteinuria and early 
postnatal death, CD2AP knock-out 
resulted in renal failure by seven 
weeks of age (Shih et al. 1999) 
and knock-out of alpha-actinin-
4 (Kos et al. 2003) caused severe 
glomerular disease and premature 
death. Fat1 knock-out presented 
as loss of slit diaphragms, severe 
podocyte foot process effacement 
and perinatal death (Ciani et 
al. 2003). The serious defects in 
these human diseases and animal 
models illustrate the crucial 
importance of these molecules in 
the proper fi ltration function of 
the kidney.
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Figure 2. Schematic drawing of the podocyte foot processes and the slit 
diaphragm area. Podocyte foot processes are attached to the underlying 
glomerular basement membrane and interconnected by a structure called 
the slit diaphragm (A). Closer view of the slit diaphragm including some of 
the established molecules and densin and fi ltrin which has been suggested to 
be localised at the fi ltration slit (Ahola et al. 2003; Ihalmo et al. 2003) (B).
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2.3 Lymphoid tissues
Lymphoid tissues mainly 
consist of dense accumulations 
of lymphocytes and they are also 
the sites of proliferation and 
differentiation of these cells. 
The lymphoid organs are divided 
into two groups, the primary 
lymphoid organs including the 
bone marrow and the thymus, 
and secondary lymphoid organs 
like the lymph nodes, the spleen 
and the tonsils. Lymphoid tissues 
are typically located at sites that 
provide a possible route of entry of 
pathogens and sites that are liable 
to infections. The main function of 
the lymphoid tissues and cells is to 
protect the body against invading 
pathogens. The immune system 
has the ability to distinguish the 
body’s own tissues and molecules 
from external antigens, but when 
this capability is aberrant it can 
result in a variety of autoimmune 
diseases. Mainly, the lymphoid 
system comprises of two types 
of cells, the lymphocytes and 
the accessory cells. Lymphocytes 
include B cells, helper T cells 
(CD4+), cytotoxic T cells (CD8+), 
regulatory T cells and natural 
killer cells, and the accessory cells 
include macrophages, dendritic 
cells and follicular dendritic cells 
(Kierszenbaum 2002b).
2.3.1 Thymus
The thymus is an organ 
situated in the upper parts of the 
thorax, behind the upper four 
costal cartilages. The size of the 
thymus changes in the course 
of life, in an adult it weights 
about 10 g. The thymus is formed 
from incomplete lobules each 
of which are constructed of an 
outer darker zone, the cortex 
and a lighter central zone, the 
medulla. The thymus is necessary 
for the development of the 
recirculating pool of small, long-
lived T lymphocytes. These cells 
are mainly responsible for the 
cell-mediated part of the immune 
response (Kierszenbaum 2002b).
T lymphocyte progenitors 
formed in the bone marrow 
enter the thymus as immature 
thymocytes and in the thymus they 
mature into immunocompetent 
T cells. Most T lymphocyte 
development takes place in the 
cortex. First, the thymocytes 
proliferate and mature from 
double-negative T cells (CD4-, 
CD8-coreceptor negative) into 
double-positive T cells (CD4+, 
CD8+). This is followed by positive 
selection, a process where the 
double-positive cells are activated 
with cortical epithelial cells to 
single-positive T cells (either CD4+ 
or CD8+). This process is mediated 
by the interaction between 
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human leucocyte antigen (HLA) 
class I or class II molecules in the 
cortical epithelial cells and the T 
cell receptors in the T cells. The 
T cell receptor has to recognise 
the own HLA molecule with 
suffi cient and appropriate affi nity. 
Subsequently, the process called 
negative selection eliminates T 
cells which bind with too high 
affi nity to own HLA molecules 
and the T cells which recognise 
self-antigens. Negative selection 
is mostly performed in the thymic 
medulla, which has an important 
function in the development of 
self-tolerance, the tolerance to 
peripheral self-antigens. A small 
minority of thymic cells (1-3%), 
the medullary thymic epithelial 
cells, express small amounts of a 
wide variety of tissue-restricted 
self-antigens, eg. proinsulin, 
which results in tolerance of 
these antigens when the cells of 
the lymphoid system encounter 
these antigens elsewhere in the 
body (Derbinski et al. 2005; Wing 
et al. 2006). Only about 5% of the 
original thymocytes survive the 
selection processes. Finally, the 
T cells migrate from the thymic 
medulla into the blood stream 
and further to the T lymphocyte 
areas of the secondary lymphoid 
organs. Since the function of the 
thymus is to produce lymphocytes 
for the other lymphoid tissues, it 
is classifi ed as a primary lymphoid 
organ.
2.3.2 Lymph nodes
Lymph nodes are small, 
fl attened, oval shaped organs, 
which are located in the course of 
the collecting lymph vessels. Their 
size varies from a few millimeters 
to more than two centimeters. 
The role of lymph nodes is to 
defend against lymph-borne 
micro-organisms (bacteria, viruses 
and parasites) and maintain and 
produce antigen specifi c B cells. 
In lymph nodes, the B- and T 
cells, follicular dendritic cells, 
macrophages and reticular cells 
are found. The lymph enters the 
lymph node through afferent 
lymph vessels and subsequently 
fl ows into the subcapsular 
space. The lymph fl ow continues 
thereafter through sinuses 
towards the efferent lymph 
vessels, which exit from the hilus 
of the lymph node (Kierszenbaum 
2002b).
The lymph node is divided 
into a cortex and a medulla. In 
the outer cortex of the lymph 
node the B- and T lymphocytes 
are organised into spherical 
masses, the lymphoid follicles 
(Figure 3). As a result of antigen 
stimulation, the antigen-specifi c 
B cells and antigen-activated 
helper T cells interact outside the 
lymphoid follicles. This results in 
the activation of B cells, and the 
activated B cells subsequently 
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Figure 3. Structure of the lymphoid follicle, modifi ed from Kierszenbaum et 
al (Kierszenbaum 2002b). The lymphoid follicle comprises of the germinal 
centre and the mantle zone. CD4+ helper T cells activate B cells by secreting 
lymphokines such as IL-4 and IL-5. The B cells then proliferate in the germinal 
centre. The mature B cells establish a contact with follicular dendritic cells, 
which display intact antigens on their cell surface. Subsequently the mature B 
cells accumulate in the mantle zone. Macrophages phagocytose the apoptotic 
B cells. Stroma of reticular fi bers surrounds the lymphoid follicle.
Mantle zone with
mature B cells
CD4+ helper T cells
Macrophage
Follicular dendritic cell
Germinal center
with proliferating
B cells
Reticular fibers
migrate to the nearby follicles 
forming structures called germinal 
centres. The germinal centres are 
the sites of B cell proliferation 
and maturation and the helper T 
cells provide proliferative signals 
necessary for B cell expansion. 
Follicular dendritic cells form a 
close contact with the maturing 
B cells and they introduce intact 
antigen-antibody complexes for 
recognition by these cells. This is 
a process vital for the rescue of 
the mature B cells from apoptosis 
(Cozine et al. 2005). 
2.3.3 Spleen
The spleen is the largest 
secondary lymphoid organ in 
the body, the average size being 
about 10 centimeters in diameter. 
It is located in the upper-left 
part of the abdomen below the 
diaphragm. Unlike the lymph 
nodes, the spleen is connected to 
the blood stream. The spleen clears 
the blood of aged blood cells and 
foreign particles and is the site of 
immune reactions to blood-borne 
antigens (Kierszenbaum 2002b). 
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Most of the spleen is composed 
of the macrophage- and red 
blood cell-occupied tissue called 
the red pulp. Its role is to remove 
the damaged and aged red blood 
cells and micro-organisms from 
blood circulation. The red pulp 
is also a storage place for red 
blood cells. Within the red pulp 
there are small, oval or rounded 
white areas, the white pulp, 
which is formed of lymphoid 
tissue. The white pulp is similar in 
cell composition to lymph nodes 
and it reacts to microorganisms 
and other foreign molecules that 
reach the bloodstream. Germinal 
centres in the white pulp are sites 
of B lymphocyte proliferation 
(Kierszenbaum 2002b).
2.3.4 Tonsils
Tonsils are accumulations of 
lymphatic tissues found at the 
openings of the respiratory and 
digestive tracts. Tonsils are at 
their largest during childhood 
and later in life the size is reduced. 
Palatine tonsils are situated in the 
lateral wall of the oropharynx,  
lingual tonsils are located in the 
lamina propria at the root of the 
tongue, and  pharyngeal tonsils 
or adenoids are situated at the 
upper posterior part of the throat 
(nasopharynx). These three types 
of tonsils are collectively named 
as the Waldeyer’s ring. These 
are the sites where an organism 
comes into contact with various 
foreign agents in the air and 
in food. Thus, the tonsils act as 
part of the immune system to 
help to protect the body against 
infection, particularly against 
pharyngeal and upper respiratory 
tract infections (Nave et al. 2001; 
Ross et al. 2003b).
The tonsils have efferent 
lymph vessels but the afferent 
lymph vessels are lacking. Hence 
the antigen exposure occurs 
across a specialised epithelium, 
the lymphoepithelium, covering 
the tonsils. The epithelium 
of the palatine and lingual 
tonsils forms deep crypts in the 
lymphoid tissue, which results in 
an increase of the surface area. 
This facilitates the contact of 
antigens with the immune cells. 
Tonsillar lymphoid tissue consist 
mainly of B lymphocytes, which, 
similarly to lymph nodes, form 
lymphoid follicles with follicular 
dendritic cells and T lymphocytes. 
Other areas are occupied by 
T lymphocytes, activated B 
lymphocytes and other cells of the 
immune system (Nave et al. 2001; 
Ross et al. 2003b).
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2.4 Diabetes
Diabetes is a chronic condition 
which occurs when the pancreas 
does not produce enough insulin or 
when the body can not effectively 
use the insulin it produces. This 
results in an inbalance of glucose 
homeostasis in the body and in a 
rise of blood glucose level. There 
are two main forms of diabetes, 
type 1 and type 2. Type 1 diabetes 
is an autoimmune disease 
typically diagnosed at a young 
age, whereas type 2 diabetes 
can be characterised as a lifestyle 
disease of middle-aged or older 
people. According to the World 
Health Organisation the number 
of all diabetes patients in the 
year 2000 was 171 million and the 
number is estimated to double in 
the next thirty years (www.who.
int/diabetes/facts/world_figures/
en/).
2.4.1 Type 1 diabetes
Type 1 diabetes is a chronic 
infl ammatory disease where 
insulin producing beta cells in the 
Langerhans islets of the pancreas 
are destroyed by an autoimmune 
mechanism. This eventually leads 
to total insulin defi ciency and as 
a consequence, inability of the 
cells to utilise blood glucose. Both 
cellular and humoral immune 
responses have been observed in 
the disease process. The current 
view of the disease progression 
is that antigen presenting cells 
(dendritic cells), which have 
picked up soluble beta cell 
proteins or proteins derived from 
apoptotic or necrotic beta cells, 
present these peptides to T cells 
in the pancreatic lymph nodes. 
The activated T cells then migrate 
to the pancreas (insulitis) and 
recognise the respective epitopes 
there. This results in a cell mediated 
response when macrophages and 
autoreactive T cells damage and 
kill the beta cells. Intracellular 
proteins are released from the 
damaged islet cells, B lymphocytes 
recognise these as foreign, and 
fi nally, start producing antibodies 
against these antigens. At the 
time of diagnosis, there is end-
stage insulitis and most (80-90%) 
of the beta cells are lost (Mathis 
et al. 2001; Daneman 2006). In 
the fi rst phases, the symptoms of 
type 1 diabetes are usually very 
sudden and they include a high 
level of glucose in the blood and 
urine, excessive thirst, frequent 
urination, hunger and weight 
loss, weakness, blurred vision, 
nausea and irritability. Patients 
with type 1 diabetes will not 
survive without constant insulin 
replacement therapy. 
The incidence of type 1 diabetes 
has been increasing considerably 
during the last decades, especially 
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among young children in 
developed countries. The increase 
in the incidence has been about 2-
5% per year worldwide (Daneman 
2006). Finland is the country with 
the highest incidence of type 1 
diabetes (Karvonen et al. 2000) 
and the current estimation of the 
number of patients is more than 
30 000 (www.diabetes.fi ).
2.4.2 Type 2 diabetes
Type 2 diabetes is a lifestyle-
dependent disease associated 
with the metabolic syndrome. 
The typical features of the 
metabolic syndrome in addition 
to hyperglycemia are obesity 
(especially abdominal obesity), 
hypertension, dyslipidemia (high 
LDL (low-density lipoprotein), 
cholesterol and triglyserides) 
and microalbuminuria. They are 
all important cardiovascular risk 
factors (Alberti et al. 1998).
Type 2 diabetes presents with 
reduced insulin sensitivity in 
insulin sensitive tissues, such as 
the liver and the adipose tissue, 
as well as with defective insulin 
secretion by the beta cells. In 
the early stages of the disease 
the predominant abnormality 
is reduced insulin sensitivity, 
characterised by elevated levels of 
insulin and glucose in the blood. 
The symptoms of type 2 diabetes 
are similar to type 1 diabetes but 
they develop more gradually, and 
some people with type 2 diabetes 
are even asymptomatic. Patients 
with incipient type 2 diabetes are 
treated by controlling of weight 
and diet as well as by increased 
physical activity. Pharmaceuticals 
are needed in most cases for blood 
glucose management: drugs to 
enhance the insulin sensitivity in 
tissues and insulin administration 
in the cases with impaired insulin 
secretion.
According to the International 
Diabetes Federation there are 
estimated to be at least 140 
million people in the world with 
type 2 diabetes (www.idf.org). 
The number of diagnosed type 
2 diabetic patients in Finland is 
about 200 000. Additionally, many 
people are unaware of having the 
disease (Reunanen 2004). 
2.4.3 LADA
LADA (latent autoimmune 
diabetes in adults) is phenotypically 
categorised as a subtype of type 
2 diabetes but it appears to be 
a type 1 and type 2 diabetes 
intermediate. It has also been 
categorised as slowly developing 
type 1 diabetes. Typical features of 
LADA are that the patients do not 
need insulin replacement therapy 
at the time of diagnosis and at 
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least during the fi rst 6 months and 
insulin defi ciency develops during 
the fi rst few years. Thus, beta cell 
failure is slower than in classical 
type 1 diabetes. The symptoms 
of metabolic syndrome are more 
seldom in LADA patients than 
in patients with type 2 diabetes. 
LADA patients account for about 
10% of the phenotypically type 
2 diabetic patients older than 
35 years (Stenstrom et al. 2005; 
Tuomi 2005).
2.4.4 MODY
MODY (maturity-onset 
diabetes of the young) is a 
monogenic form of diabetes which 
manifests mostly in individuals 
with strong family history of 
diabetes. MODY typically starts at 
a young age (before age 25) and 
the patients do not require insulin 
therapy at the beginning, but later 
on insulin secretion is defective. 
The diabetic complications, 
including features of metabolic 
syndrome, are usually absent 
or mild. The severity of insulin 
secretion defect and other clinical 
symptoms varies in different 
MODY subtypes (Timsit et al. 
2005). MODY3 seems to be the 
most common form of MODY in 
Scandinavia (Lehto et al. 1999). An 
estimation is that MODY accounts 
for less than 5% of all cases of 
diabetes (Velho et al. 1998). 
2.5 Risk factors for diabetes
2.5.1 Genetic factors
Genetic susceptibility appears 
to be a prerequisite for type 
1 diabetes and unknown 
environmental triggers determine 
who amongst susceptible people 
develop the disease (Daneman 
2006). A strong familial 
aggregation is seen in the type 
1 diabetes cases since about 10-
13% of newly diagnosed children 
with type 1 diabetes have a fi rst 
degree relative with the disease 
(Achenbach et al. 2005). The 
major determinants of the genetic 
predisposition to type 1 diabetes 
are the genes located in the HLA 
class II locus on chromosome 6 
(Ilonen et al. 2002). The role of the 
molecules encoded by these genes 
is to present peptides derived 
from phagocytosed extracellular 
proteins to CD4+ (helper) T cells. 
The HLA class II molecules are 
expressed on the cell surfaces 
of specifi c antigen presenting 
cells, eg. B cells, dendritic cells 
and macrophages. Variants 
of HLA genes are thought to 
confer about 50% of the genetic 
susceptibility. The disease risk or 
probability is mainly defi ned by 
HLA DQ molecules. The high risk 
genotypes include DQA1*0301-
DQB1*0302 (encoding protein 
HLA-DQ8), DQA1*0501-
DQB1*0201 (encoding protein 
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HLA-DQ2) and DQA1*0301-
DQB1*0201 (also encoding 
protein HLA-DQ2) (Ilonen et 
al. 2002). HLA-DR molecules 
and probably also other loci 
within the HLA region have a 
modifying effect on the HLA DQ 
defi ned genetic risk (She 1996). 
Thus the DQ8 haplotypes with 
HLA-DRB1*0403 or DRB1*0406 
are associated with protection 
against the disease whereas DQ8 
haplotypes with other DRB1*04 
alleles are associated with 
disease risk. The protective HLA 
haplotypes include also (DR2)-
DQA1*0102-DQB1*0602, (DR14)-
DQA1*01-DQB1*0503 and (DR7)-
DQA1*0201-DQB1*0303 (Ilonen 
et al. 2002). The individual risk 
is ultimately determined by the 
specifi c combination of risk and 
protection associated haplotypes.
Two other genes, CTLA-4 
(cytotoxic T lymphocyte antigen-
4) and insulin (INS) are thought 
to explain about 15% of the 
diabetes susceptibility (Daneman 
2006). A VNTR (variable number 
of tandem repeats) and a series of 
associated SNPs (single nucleotide 
polymorphisms) in the insulin 
gene region have been associated 
with type 1 diabetes (Bennett 
et al. 1996). A variant of the 
gene PTPN22 (protein tyrosine 
phosphatase 22) (Bottini et al. 
2004; Smyth et al. 2004), coding 
a suppressor of T cell activation, 
has been associated with type 1 
diabetes as well. However, the 
HLA, CTLA-4 and PTPN22 genes 
have also been linked with other 
autoimmune diseases (Becker 
1999; Bottini et al. 2004; Smyth et 
al. 2004), supporting the thought 
that overlapping biological 
pathways may contribute to 
different autoimmune diseases. In 
addition, more than ten other loci 
have been associated with type 1 
diabetes (Concannon et al. 1998; 
Mein et al. 1998; Cox et al. 2001). 
Type 1 and type 2 diabetes have 
been reported to have strong 
familial clustering: increasing 
frequency of type 2 diabetes has 
been detected in families with 
type 1 diabetes cases and type 1 
diabetes cases in families with type 
2 history. This suggests a common 
genetic susceptibility (Tuomi 2005). 
However, the genes associated 
with type 2 diabetes are still poorly 
known (Hansen et al. 2005). 
LADA and MODY have been 
shown to have a genetic component 
as well. Patients with LADA appear 
to share the HLA conferred genetic 
susceptibility with type 1 diabetes 
since they have an increased 
frequency of HLA susceptibility 
alleles (Tuomi 2005). MODY is a 
dominantly inherited disease and 
mutations in six genes cause the 
majority of disease cases (Timsit et 
al. 2005).
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2.5.2 Environmental factors
The genetic factors are 
not responsible alone for the 
development of type 1 diabetes 
and environmental triggers and 
accelerators are required for the 
process. The signifi cant role of 
environmental factors is indicated 
by the rapid increase in diabetes 
incidence. It addition, not all 
of identical twins have type 1 
diabetes (Barnett et al. 1981; 
Kaprio et al. 1992; Kyvik et al. 
1995), also suggesting the crucial 
role of environmental factors in 
the disease development.
Various environmental 
and dietary factors have been 
suggested to be either risk factors 
or factors protecting against type 
1 diabetes. The risk candidates 
include N-nitroso compounds 
(Helgason et al. 1981), cereals 
(Norris et al. 2003) and cow’s 
milk. The effect of diet especially 
during infancy appears to be 
important, as it seems that early 
introduction of cow milk formula 
feeding could be diabetogenic and 
breastfeeding should be preferred 
(Vaarala et al. 1999; Virtanen et 
al. 2003; Sadauskaite-Kuehne et 
al. 2004). However, the results of 
the dietary and environmental 
factors on type 1 diabetes 
development are inconsistent 
and further studies are needed. In 
addition, virus infections during 
gestation and infancy, especially 
certain enterovirus, rotavirus 
and rubella infections, have 
been proposed to be associated 
with the development of type 1 
diabetes (Ginsberg-Fellner et al. 
1985; Hyoty et al. 1995; Horwitz 
et al. 1998; Honeyman et al. 2000). 
The factors suggested to protect 
against type 1 diabetes include 
nicotinamide, zinc, and vitamins 
C, D and E (Virtanen et al. 2003). 
Environmental factors appear 
to be the main determinant of 
type 2 diabetes. Dietary factors, 
in particular high fat, high sugar, 
high salt and low fi ber are central 
for the development of type 2 
diabetes, in addition to other 
factors such as smoking and lack 
of exercise.
2.6 Humoral immunology 
of diabetes
2.6.1 History of autoantibodies
Bottazzo and colleagues 
were the fi rst to discover by 
immunofl uorescence that 
circulating autoantibodies 
against islets of Langerhans 
antigens exist in patients with type 
1 diabetes (Bottazzo et al. 1974). 
Now it is known that these islet 
cell autoantibodies (ICAs) consist 
of many different antibodies 
against various intracellular islet 
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cell antigens. The next important 
fi nding was made in 1983 when 
Palmer and colleagues detected 
autoantibodies against insulin 
(IAA) from diabetic patients 
serum by a radioimmunoassay 
(Palmer et al. 1983). In 1990, 
Baekkeskov and colleagues 
identifi ed by immunoblotting a 
pancreatic beta cell autoantigen 
sized 64 kDa to be glutamic 
acid decarboxylase (GAD), the 
biosynthesising enzyme of 
the neurotransmitter GABA 
(Baekkeskov et al. 1990). GAD is a 
molecule expressed in high levels 
in some CNS neurons (McLaughlin 
et al. 1975) and in pancreatic 
beta cells (Okada et al. 1976). 
Two isoforms of GAD (GAD65 
and GAD67) have been identifi ed 
(Karlsen et al. 1991; Michelsen 
et al. 1991) and both isoforms 
are expressed in the brain and 
the pancreatic islets. The 65 kDa 
isoform is the predominant form 
in the pancreas. 
Christie and colleagues 
discovered in 1993 that type 
1 diabetic patients have 
autoantigens sized 64 kDa which 
were distinct from GAD (Christie 
et al. 1993) and in 1994 it was 
shown that the islet cell antigen 
512 (ICA512) is related to protein 
tyrosin phosphatases (Rabin 
et al. 1994). Finally in 1996, 
Lan and colleagues named this 
molecule as IA-2 (islet antigen 
2) (Lan et al. 1996). Nowadays, 
these four autoantibody types 
(ICA, IAA, GAD65A, IA-2A) 
are tested from serum when 
predicting or diagnosing type 1 
diabetes and they have gained 
a status as established markers 
of preclinical type 1 diabetes. 
ICA is tested by an indirect 
immunofl uorescence method and 
IAA, GADA and IA-2A are tested 
by a radioimmunoprecipitation 
assays.
Recently, other autoantibodies 
in addition to the established ones 
have been searched for in patients 
with type 1 diabetes. Antibodies 
against antigens predominantly 
expressed in other tissues than 
pancreas, e.g. against vascular 
wall proteins such as elastin 
(Nicoloff et al. 2000) and basement 
membrane protein collagen type 
IV (Nicoloff et al. 2002), have 
been detected. Many of these 
antibodies against non-pancreatic 
tissues are present in human serum 
in several diseases, thus they are 
not useful in diabetes prediction 
or diagnosis. Antibodies to CD38 
(ADP ribosyl cyclase/cyclic ADP-
ribose hydrolase) have also been 
found from a minority of type 1 
and type 2 diabetic patients but 
they either have not proved to 
be useful in predicting diabetes 
(Mallone et al. 2006).
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2.6.2 Mechanism of the 
humoral autoimmunity
Type 1 diabetes is characterised 
by the appearance of diabetes-
associated autoantibodies in the 
preclinical period, which likely 
refl ects the ongoing beta cell 
damage. The series of events 
associated with the formation 
of autoantibodies against the 
pancreatic islet antigens are not 
well characterised. However, 
autoantibody production has been 
suggested to be a consequence 
of the T cell mediated beta cell 
destruction and the following 
processing of various intacellular 
beta cell autoantigens. This could 
result in B lymphocyte activation 
and autoantibody production 
(Falorni et al. 2003). It is not known 
why the normal suppression of 
autoreactivity fails in patients with 
type 1 diabetes. It is either not 
known whether autoantibodies 
are critically involved in the 
initiation or progression of the 
disease (Roep 2003).
Epitope spreading is 
the mechanism by which 
autoantibodies against multiple 
antigens are thought to develop 
in type 1 diabetes. It is a process 
whereby the initial immune 
response against one inducing 
epitope is extended to other 
epitopes distinct from and non-
cross-reactive with the original 
epitope. Thus a wide variety of 
epitopes can become targets of 
the ongoing immune response. 
Spreading of autoimmunity is 
observed within one molecule but 
also between different molecules 
(Achenbach et al. 2005).
2.6.3 Appearance and 
prevalence of autoantibodies
The latent preclinical phase of 
type 1 diabetes may last for several 
years but in some cases the disease 
progresses into clinical diabetes 
within a few months; it appears 
to be that younger individuals 
with the autoantibodies progress 
faster to the clinical disease than 
older persons (Daneman 2006). 
At the time of diagnosis, almost 
all subjects with diabetes are 
autoantibody positive (Sabbah et 
al. 1999).
The genetically susceptible 
children who develop diabetes-
associated autoantibodies early 
in infancy typically develop type 1 
diabetes in early childhood. They 
often develop autoantibodies 
already before the age of 2 years. 
These children most often develop 
multiple islet autoantibodies and 
the prevalence of autoantibody 
positivity increases with age 
(Ziegler et al. 1999; Kimpimaki 
et al. 2001; Hummel et al. 2004). 
The order of diabetes-associated 
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autoantibody appearance usually 
is fi rst IAA, then GADA and IA-2A 
in these individuals (Achenbach 
et al. 2005). On the contrary, 
children who develop the fi rst 
autoantibodies later in their 
life have slower progression to 
multiple autoantibodies and to 
type 1 diabetes (Hummel et al. 
2004). Specifi c HLA genotypes 
appear to have an infl uence 
on the timing of appearance 
of autoantibodies and the 
magnitude and extent of the 
autoimmune response (Schenker 
et al. 1999; Yu et al. 2000; Knip et 
al. 2002; Hermann et al. 2005).
The persistence of diabetes-
associated antibodies from the 
time of diabetes diagnosis to 
ten years after diagnosis was 
studied by Savola et al (Savola 
et al. 1998b). The concentrations 
and prevalences of IA-2A and ICA 
decreased considerably during 
the course of the disease, but still 
after 10 years 67% of the subjects 
had at least one autoantibody 
detectable. GADA levels showed 
substantial fl uctuation during 
the ten year follow-up period. 
Generally, the prevalence 
of the diabetes-associated 
autoantibodies has a tendency 
to decrease after the diagnosis of 
the disease.
The current view is that the 
more antibody types detected, the 
greater the possibility to develop 
clinical diabetes, e.g. subjects who 
have positivity for 3-4 antibodies 
have a 60-100% risk of developing 
type 1 diabetes over the next 5-10 
years (Verge et al. 1996; Gardner 
et al. 1999; LaGasse et al. 2002). 
However, many who have signs 
of beta cell autoimmunity do not 
progress to the clinical disease 
(Knip 2002). Recent reports have 
suggested that a combination of 
autoantibody screening and HLA 
genotype screening (Kupila et al. 
2001; Decochez et al. 2005), the 
deciphering of the distribution of 
various immunoglobulin G (IgG) 
subclasses and reactivities against 
specifi c epitopes (Achenbach et 
al. 2004) or the IA-2A screening 
alone (Decochez et al. 2002; 
Knip et al. 2002; Decochez et al. 
2005) would be more appropriate 
markers of developing diabetes. 
It has also been suggested that 
GADA would be rather markers 
of general autoimmunity than 
type 1 diabetes (Knip et al. 2002). 
The autoantibody profi le varies 
with the age at onset and sex; in 
subjects of different ages, different 
autoantibodies are regarded as 
more sensitive predictors of the 
development of diabetes (Pihoker 
et al. 2005).
In addition to patients 
with classical type 1 diabetes, 
the diabetes-associated 
autoantibodies are detected in 
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LADA patients. Typically LADA 
patients have GAD antibodies but 
also other islet autoantibodies 
are detected. In LADA patients 
similarly to type 1 diabetes patients 
the number of autoantibody types 
detected seems to correlate with 
the speed of beta cell loss; the 
more antibody types detected the 
faster the beta cell deterioration 
(Stenstrom et al. 2005).
2.7 Diabetic nephropathy
Diabetic nephropathy (DN) is 
a severe complication of diabetes 
affecting approximately 25-40% 
of both type 1 and type 2 diabetic 
patients. Poor glycemic control 
seems to be a prerequisite for the 
kidney disease and the fi rst signs 
of DN generally appear within 
5-15 years of diabetes duration. 
DN is the single most common 
disease leading to renal failure in 
adults and a major cause for high 
mortality rates in diabetic patients 
(Gross et al. 2005).
The onset of DN is associated 
with an increased glomerular 
fi ltration rate (GFR). The 
subsequent stages present with 
elevated blood pressure and 
damage of the kidney glomerular 
fi ltration barrier resulting in the 
loss of large blood proteins, 
such as albumin into the urine 
(proteinuria). This is followed 
by progressive scarring of the 
kidney tissue and, ultimately, 
end-stage renal disease with 
decline in GFR and total loss of 
kidney function. The series of 
structural changes detected in 
the kidney glomerulus include 
thickening of the glomerular 
basement membrane, glomerular 
mesangial cell growth, mesangial 
matrix expansion, mesangial 
sclerosis (Mogensen 1976) and 
podocyte loss (Pagtalunan et 
al. 1997; White et al. 2002). 
In addition, the expression of 
the key molecule of the slit 
diaphragm, nephrin, is altered 
in DN (Doublier et al. 2003). 
The risk factors for DN in 
addition to hyperglycemia 
include increased blood pressure 
levels, smoking, elevated serum 
lipids and dietary factors such as 
the amount and source of protein 
(Gross et al. 2005). Genetic 
predisposition has also been 
suggested as a risk factor (Rich 
2006; Sale et al. 2006) but, thus 
far, none of the DN associated 
genes have been shown to have 
as signifi cant a role in the disease 
process as HLA genes have in 
type 1 diabetes.
The mechanisms by which the 
increased intra- and extracellular 
glucose concentration in 
diabetic patients could lead 
to kidney damage have been 
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suggested to include increased 
oxidative stress (Giugliano et al. 
1996), advanced glycation end-
product formation, activation 
of various signaling pathways, 
increased polyol and hexosamine 
pathway fl ux (Brownlee 2001) 
and downregulation of nephrin 
expression in the podocytes 
(Doublier et al. 2003; Menne et al. 
2006). In addition, infl ammation, 
including infi ltration of 
lymphocytes into the kidney 
tissues and production of 
cytokines, chemokines and growth 
factors, has been implicated with 
the development of DN (Bohle 
et al. 1991; Furuta et al. 1993; 
Saraheimo et al. 2003; Navarro et 
al. 2005). 
Diabetic nephropathy is 
categorised in stages on the basis 
of the urinary albumin excretion 
rate (AER): microalbuminuria 
as AER between 30-300 mg/
24h or 20-200 µg/min and 
macroalbuminuria/proteinuria 
as AER >300 mg/24h or >200 µg/
min. Microalbuminuria is used 
as a marker for DN (Mogensen 
et al. 1984). Recently, Caramori 
and colleagues suggested that 
looking at the combination of 
patient parameters (eg. AER, 
family history, blood pressure, 
plasma lipid levels) instead of 
the AER alone would be more 
accurate in the assessment of 
the DN risk (Caramori et al. 
2006). Strict glycemic and blood 
pressure control have been 
proven successful in slowing 
down the clinical and structural 
manifestations of DN in type 1 
diabetic patients in many studies, 
but despite these advancements 
the cases of diabetic kidney disease 
are still increasing (Caramori et al. 
2006).
2.7.1 Autoimmunity in diabetic 
nephropathy
Already in the 1970s, Mauer 
and colleagues found linear 
deposits of immunoglobulin and 
complement in the glomeruli of 
diabetic rats (Mauer et al. 1972). 
Since then autoimmunity has 
been suggested as one of the 
mechanisms participating in the 
development of DN. Interestingly, 
in the CNF patients who have 
undergone a renal transplant, the 
recurrence of severe proteinuria 
has been suggested to be caused 
at least partially by nephrin 
antibodies (Wang et al. 2001; 
Patrakka et al. 2002). This implies 
that the antigens of the podocyte 
cells in the kidney glomerulus 
are accessible to circulating 
antibodies.
There are few studies which 
have considered the association 
of specifi c autoantibodies with 
DN. However, no association 
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has been detected between the 
established diabetes-associated 
autoantibodies, GADA and ICA, and 
diabetic complications (Roll et al. 
1995; Vinik et al. 1995), suggesting 
that these autoantibodies have 
no pathogenic role in longlasting 
diabetes and DN. Autoantibodies 
against the glycosphingolipid 
sulphatide, a molecule expressed 
in the neurons (Fredman et al. 
1991), in the pancreatic Langerhans 
islets and in the kidneys (Buschard 
et al. 1993), have been detected 
in patients with type 1 diabetes 
(Buschard et al. 1993) but the data 
did not suggest an association 
of these antibodies to diabetic 
complications (Andersson et 
al. 2002). The prevalence and 
signifi cance of phospholipid 
autoantibodies in the circulation 
of diabetic patients has also been 
studied, but they did not appear 
to be associated with DN (Vinik et 
al. 1995).
Oxidised and glycated proteins 
are commonly found in diabetic 
patients as a results of increased 
hyperglycemia and oxidative 
stress (Giugliano et al. 1996). 
Oxidised LDL is also known to be 
immunogenic. Autoantibodies 
against glycated and oxidased 
LDL in diabetic patients have not 
been shown to associate with DN 
(Korpinen et al. 1997; Leinonen 
et al. 1998), but interestingly, 
high concentrations of oxidised 
LDL-anti-oxidised LDL complexes 
were associated with proteinuria 
(Atchley et al. 2002). These results 
suggest that hyperglycemia 
and hyperlipidemia seen in 
diabetic patients can induce the 
formation of immune complexes, 
which could play a role in the 
pathogenesis of diabetes-
related vascular complications; 
the immune complexes could 
be deposited in the small blood 
vessels of microcirculation, eg. 
in small glomerular vessels. 
This view was strengthened 
by the fi nding of Nicoloff and 
colleagues who showed that 
circulating immune complexes 
associate with the development 
of microvascular complications in 
diabetic children (Nicoloff et al. 
2004).  Albeit the many studies 
considering autoantibodies in 
diabetic nephropathy, none 
of the reports have been able 
to demonstrate that specifi c 
antibodies would have an active 
role in the development of the 
diabetic kidney disease.
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The aim of this thesis work was to systematically study the expression 
of nephrin in human lymphoid cells and tissues, and furthermore, to 
decipher if there are podocyte proteins in the pancreas with similarities 
with the complex in the slit diaphragm area. In addition, I explored the 
possibility whether nephrin, densin and fi ltrin can act as autoantigens 
and if autoantibodies against these molecules can be detected in the 
serum of patients with type 1 diabetes. The possible association of 
these autoantibodies to diabetic nephropathy was also deciphered.
The specifi c aims of this thesis work were:
• To fi nd out whether other slit  diaphragm-associated proteins        
than nephrin can also be found in pancreatic islet cells
• To determine the expression of nephrin in lymphoid cells and 
tissues
• To identify nephrin autoantibodies (NAA) in serum samples of 
patients with type 1 diabetes
• To identify densin and fi ltrin autoantibodies (DAA and FAA) in 
serum samples of patients with type 1 diabetes
• To study the association of NAA, DAA and FAA with developing 
diabetic nephropathy
3 Aims of the study
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4.1 Human study subjects
4.1.1 University of Oulu patient 
material (Publication III, IV)
The autoantibody study 
population comprised of children 
and adolescents (Table 3) 
diagnosed with type 1 diabetes 
at the Department of Paediatrics, 
University of Oulu, Finland 
between 1983 and 1986 (Savola 
et al. 1998b). The total follow-up 
period for the detection of diabetic 
complications was 17-19 years. 
In addition to the patient serum 
samples, samples of the Finnish 
healthy control population (Table 
3), gathered between the years 
1989-1994, were measured, and 
the results were used to defi ne 
the cut-off limits for autoantibody 
positivities. All samples were 
stored at –20°C until analysed. 
4 Subjects, materials and methods
Detailed clinical data of 
the samples as well as titres 
of four established diabetes-
associated autoantibodies, i.e. 
ICA, GADA, IAA and IA-2A were 
available (Savola et al. 1998a). 
Normoalbuminuria was defi ned 
as albumin excretion rate of less 
than 30mg/24h, microalbuminuria 
as 30-300mg/24h and proteinuria/
macroalbuminuria as more than 
300mg/24h. During the time of 
this study, 10 patients dropped 
out from the follow up. Of these 
patients nine had moved to 
another region in Finland and one 
had died from multiple sclerosis. 
The mean duration of diabetes 
when patients dropped out from 
the study was 8.7 years (range 4 
to 13 years).
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NAA study
Patients
Healthy subjects
DAA study
Patients
Healthy subjects
FAA study
Patients
Healthy subjects
Number
of subjects
66
96
66
90
66
77
Gender
Male/female
 
43/23
48/48
 
43/23
43/47
 
43/23
39/38
Mean age at
diagnosis in years
8.2
11.3
8.2
11.4
8.2
11.1
Serum sample 
timepoints 
(years from diagnosis)
 0, 2, 5, 10
0
 
0, 2, 5, 10
0
 
0, 2, 5, 10
0
Table 3. University of Oulu study material utilised in the nephrin, densin and 
fi ltrin autoantibody studies. The gender distribution and mean age of the 
subjects are indicated. There was a variation in the number of healthy subjects 
in each assay. NAA, nephrin autoanti-bodies; DAA, densin autoantibodies; 
FAA, fi ltrin autoantibodies.
4.1.2 FinnDiane patient material 
(unpublished)
Serum samples from a subset 
(n=150) of type 1 diabetic patients 
from an ongoing nationwide, 
multicentre Finnish Diabetic 
Nephropathy Study (FinnDiane) 
were utilised in this study 
(Saraheimo et al. 2003). The patients 
were divided into three groups 
according to their AER from three 
consecutive overnight or 24-h urine 
collections: normoalbuminuric 
(n=50), microalbuminuric (n=50) 
and macroalbuminuric (n=50). 
Type 1 diabetes was defi ned as an 
onset of diabetes before the age 
of 35 years and permanent insulin 
treatment initiated within one 
year of diagnosis. The duration of 
diabetes required was at least ten 
years. The mean age of the patients 
was 36.0 years, mean age of onset 
of diabetes was 13.4 years and the 
mean diabetes duration was 22.6 
years. Patients with normal AER had 
no antihypertensive medication 
but patients with microalbuminuria 
and macroalbuminuria had 
angiotensin converting enzyme 
inhibitor treatment. Thirty fi ve 
healthy control subjects were 
included in the study. Detailed 
clinical data were available 
including clinical history, data 
on medication, cardiovascular 
status, diabetic complications, 
total glycated hemoglobin and 
creatinine (Saraheimo et al. 2003).
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4.2 Tissues and cells
4.2.1 Tissue samples (I, II, III, IV)
Human pancreas, kidney, 
thymus, lymph nodes, tonsil, 
adenoid tissues, rat pancreas 
and kidney tissues and mouse 
pancreas tissues were used in 
these studies. Normal rat pancreas, 
rat kidney and mouse pancreas 
tissues were obtained from our 
previous experiments. Human 
pancreas and kidney tissues were 
obtained from human cadaver 
donors from Helsinki University 
Central Hospital. Human thymic 
tissue was obtained during open-
heart surgery at the Hospital for 
Children and Adolescents, Helsinki 
University Central Hospital. Lymph 
node tissues were gathered 
from the routine diagnostic 
biopsy material of the Central 
Laboratory of Pathology, Helsinki 
University Central Hospital. 
Human tonsil and adenoid 
tissues were kindly provided by 
Dr. P. Mattila (Department of 
Otorhinolaryngology, Helsinki 
University Central Hospital).
4.2.2 Isolation of cells from 
human peripheral blood (II)
Human peripheral blood 
mononuclear cells were isolated 
from buffy coat preparations 
by Ficoll/Hypaque (Pharmacia, 
Uppsala, Sweden) gradient 
separation. The monocyte 
population was enriched by 
two hours adherence to culture 
plates. The adherent cells were 
incubated in RPMI 1640 media 
(BioWhittaker, Verviers, Belgium) 
supplemented with 10% foetal 
calf serum (Life Technologies, 
GibcoBRL, Karlsruhe, Germany), 
100 U/ml penicillin/streptomycin, 
two mM glutamine in humidifi ed 
atmosphere with 5% CO2 at 37°C. 
Incubation of adherent cells in 
Macrophage-SFM medium (Life 
Technologies, Gaithesburg, MD) 
for seven days in the presence of 
600 U/ml granulocyte macrophage-
colony stimulating factor (GM-
CSF) gave rise to macrophages 
(Pirhonen et al. 2001), whereas 
presence of 500 U/ml GM-CSF 
(Roche Diagnostics GmbH, 
Mannheim, Germany) and 250 
U/ml interleukin-4 (IL-4) (Roche 
Diagnostics) for seven days gave 
rise to dendritic cells (Sallusto et 
al. 1994). By a further incubation 
with added lipopolysaccharide 
(50 ng/ml) or tumour necrosis 
factor-  (TNF- , 10 ng/ml) for 48 
hours, the dendritic cells were 
matured (Sallusto et al. 1994) and 
the macrophages were activated 
(Rodenburg et al. 1998). 
Various lymphocyte populations 
were isolated from peripheral 
blood mononuclear cells using a 
magnetic cell separation system, 
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(Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany). For the 
isolation of T lymphocytes, 
monocytes and B lymphocytes 
fl uorescein isothiocyanate (FITC)-
conjugated antibodies against, 
CD3 (Pharmingen, San Diego, CA), 
CD14 (Dako, Glostrup, Denmark) 
and CD19 (Becton Dickinson, San 
Jose, CA) were used respectively 
together with magnetic beads 
coated with anti-FITC or anti-
mouse Ig antibodies. The purity 
of the isolated cell populations 
was over 90% as verifi ed by FACS 
analysis. 
4.3 Messenger RNA (mRNA) 
expression
4.3.1 Database searches (I)
The expressed sequence tag 
(EST) libraries at the National Center 
for Biotechnology Information 
(NCBI) Unigene database (http://
www.ncbi.nlm.nih.gov/) (Wheeler 
et al. 2003) were screened to 
assess the potential expression of 
the selected podocyte molecules 
at the mRNA level in pancreatic 
tissue and in pancreatic cell lines.
4.3.2 RNA extraction and 
synthesis of complementary DNA 
(cDNA) (I, II, IV)
Total RNA was isolated with 
Trizol® reagent (Invitrogen, 
Carlsbad, CA, USA) from a variety 
of tissues and cells: human 
pancreas, kidney, thymus, adenoid 
and tonsil, cultured dendritic 
cells and macrophages and 
magnetically isolated peripheral 
blood cells. The RNA was treated 
with DNase I (Promega, Madison, 
WI, USA) and transcribed into 
cDNA using poly-T priming 
(Roche, Basel, Switzerland) and 
Moloney-Murine Leukemia Virus 
(M-MLV) reverse transcriptase 
(reverse transcriptase positive, 
RT+ sample, Promega). To confi rm 
the RNA origin of the reverse 
transcriptase-polymerase chain 
reaction (RT-PCR) signals, samples 
that were not reverse transcribed 
(RT-) were analysed in parallel 
with the RT+ samples.
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4.3.3 Reverse transcriptase-
polymerase chain reaction (RT-
PCR)  (I, II, III, IV)
The primers for RT-PCR were 
designed with the Primer3 
software (Rozen et al. 2000), and 
their specifi city was verifi ed by 
using the Blast search algorithm 
in the Genbank database at the 
NCBI (Altschul et al. 1990; Benson 
et al. 2000). The primers are 
summarised in Table 4.
The RT-PCR reactions were 
performed using EXT DNA 
polymerase (Publication I, IV) 
(Finnzymes, Espoo, Finland) or 
AmpliTaq Gold DNA polymerase 
(Publication II, III) (Perkin Elmer, 
Norwalk, CT, USA) with initial 
denaturation of cDNA at 95 °C 
for 3 min, followed by 35-40 
amplifi cation cycles (95 °C 30 s, 
56-58 °C 1 min, and 72 °C 30 s), 
and fi nal elongation at 72 °C for 
5 min. The reactions were run in 
agarose gels, the RT-PCR products 
were purifi ed and sequenced as 
described earlier (Palmen et al. 
2001). 
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Table 4. Primers and probes used in conventional RT-PCR (RT-PCR), Real-time 
quantitative RT-PCR (Q RT-PCR) and in antigen generation. The podocin 
primers which amplifi ed the podocin sequence from the pancreas are marked 
with an asterisk (*).
4.3.4 Real-time quantitative 
RT-PCR (II)
For the amplifi cation of 
human nephrin with the Taqman 
Real-time quantitative RT-PCR 
(Q RT-PCR), specifi c primers and 
FAM (6-carboxy-fl uorescein)-
labelled probe were used (Table 
4). The ubiquitin conjugating 
enzyme (UbcH5B) gene, used 
as the endogenous control, was 
amplifi ed using the sense and 
antisense primer pair as well as the 
VIC-labelled probe (Hamalainen 
et al. 2001) (Table 4). The UbcH5B 
values were used to normalise 
the amounts of nephrin. The ABI 
Prism 7700 sequence detector, 
which was used for the signal 
detection, was programmed to an 
initial step of 2 min at 50°C and 
10 min at 95°C, followed by 40 
thermal cycles of 15 s at 95°C and 
1 min at 60°C.
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4.4 Protein expression
4.4.1 Tissue and cell lysates and 
immunoblotting (I, II)
Human glomeruli were prepared 
as described by Kerjaschki et al 
(Kerjaschki et al. 1983). Rat kidney 
and pancreas tissue, human kidney, 
pancreas, thymus, adenoid and 
tonsil tissues were homogenised 
in RIPA buffer (150 mM NaCl, 1% 
NP-40, 0.5% deoxycholic acid, 
0.1% SDS, 50 mM Tris-HCl (pH 
8)), urea buffer (8 M urea, 1 mM 
dithiothreitol (DTT), 1 mM EDTA) 
or Laemmli buffer (94 mM Tris-HCl 
(pH 6.8), 13% glycerol, 3% SDS, 
7.5% 2-mercaptoethanol, 0.075% 
bromophenolblue). Cell extracts 
were centrifuged at 10 000g for 
10-30 min at 4°C. Proteins from 
the magnetically separated cell 
populations, the monocyte-derived 
dendritic cells and the monocyte-
derived macrophages were 
extracted from the phenol phase, 
obtained when isolating RNA with 
Trizol® (Life Technologies) reagent. 
Protein concentrations in protein 
extracts were determined using 
BCA Protein Assay reagent (Pierce, 
Rockford, IL, USA).
Appropriate amounts of the cell 
or tissue lysates were run through 
reducing polyacrylamide gels in the 
Protean Mini-gel electrophoresis 
system (Bio-Rad Laboratories, 
Richmond, CA, USA) and the proteins 
were transferred to nitrocellulose 
membranes (Amersham Biosciences, 
Buckinghamshire, UK) using a wet-
transfer system. After blocking in 2-
5% skimmed milk (Valio, Finland), 
the membranes were incubated 
with the primary antibodies (Table 
5) for at least one hour followed 
by incubation with appropriate 
horseradish peroxidase conjugated 
secondary antibodies (Jackson 
ImmunoResearch Laboratories, Inc., 
West Grove, PA, USA) and detection 
of the signals with SuperSignal 
ECL substrate (Pierce, Fockford, IL, 
USA). 
Primary antibody
CD2AP
Podocin
FAT
NEPH1
Filtrin
Synaptopodin
Alpha-actinin-4
Nephrin
Poly/monoclonal
P
P
P
P
P
M
M
P
Source/reference
Santa Cruz, (Shih et al. 2001)
(Roselli et al. 2002)
(Inoue et al. 2001)
(Liu et al. 2003; Sellin et al. 2003)
(Ihalmo et al. 2003)
Progen, (Mundel et al. 1997)
(Honda et al. 1998; Kaplan et al. 2000)
(Ahola et al. 2003)
Used in
I
I
I
I
I
I
I
II
Table 5. Primary antibodies used in immunoblotting experiments. 
P, polyclonal antibody; M, monoclonal antibody.
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4.4.2 Immunostaining of tissue 
sections
4.4.2.1 Immunofl uorescence 
(I, II, III, IV)
Frozen sections (4-6 µm) of 
human, rat or mouse pancreas, 
human adenoids and rat kidney 
were fi xed with acetone or 3.5-
4% paraformaldehyde for two to 
ten min, washed with phosphate-
buffered saline (PBS), blocked 
with 10% normal goat serum or 
CAS-Block (Zymed Laboratories, 
San Francisco, CA, USA), and 
incubated with the primary 
antibodies (Table 6) for one hour 
or overnight (o/n). After washes 
with PBS, the sections were further 
incubated for one hour with 
appropriate fl uorescent secondary 
antibodies. After washes, the 
sections were embedded in 
Immu-Mount embedding medium 
(Shandon, Pittsburgh, PA, USA) or 
Vectashield mounting medium 
for immunofl uorescence (Vector 
Laboratories, Inc., Burlingame, 
CA, USA). The control stainings, by 
omitting the primary antibodies 
and by pre-immune sera, were 
performed when possible. The 
sections were examined with a 
Zeiss Axiophot2 microscope (Carl 
Zeiss Jena GmbH, Jena, Germany) 
or Olympus Provis microscope 
(Olympus America Inc, FL, USA).
Antibody/serum
CD2AP 
Podocin 
FAT
NEPH1
Filtrin
Synaptopodin
Alpha-actinin-4
Nephrin (anti-rat)
Insulin
Nephrin (anti-human)
CD3
CD19
CD21
Human sera
Densin
Poly/monoclonal
P
P
P
P
P
M
M
P
M
P
P
P
M
Not determined
P
Reference/Source
Santa Cruz Biotechnology (CA,USA)
(Roselli et al. 2002)
(Inoue et al. 2001)
(Sellin et al. 2003)
Ihalmo et al, submitted
Progen (Heidelberg, Germany)
(Honda et al. 1998)
(Ahola et al. 2003)
Neomarkers (Fremont, CA, USA)
(Ahola et al. 2003)
Becton Dickinson (San Jose, CA, USA)
Dako (Glostrup, Denmark)
Dako (Glostrup, Denmark)
(Savola et al. 1998b)
(Izawa et al. 2002)
Used in
I
I
I
I
I
I
I
I, III
I, IV
II
II
II
II
III
IV
Table 6. Primary antibodies used in immunofl uorescence experiments. P, 
polyclonal antibody; M, monoclonal antibody.
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4.4.2.2 Immunohistochemistry (II)
Lymph node sections were 
deparaffi nised in xylene and 
rehydrated through graded 
concentrations of ethanol to 
distilled water. The slides were 
incubated in a microwave owen 
in 10 mM Tris-HCl, 1mM EDTA 
buffer, pH 9.0 for 20 min. The 
immunohistochemical staining 
was performed using a Lab 
Vision Autostainer (Lab Vision 
Corporation, Fremont, CA, USA) 
and ChemMate DAKO Envision 
Detection Kit (DakoCytomation, 
Glostrup, Denmark). The sections 
were incubated with a primary 
antibody against nephrin (diluted 
1:500, (Ahola et al. 2003)) for 30 
min. Rabbit IgG and antibody 
dilution buffer were used instead 
of a primary antibody as negative 
controls. The staining was 
visualised using ChemMate DAB 
chromogen (DakoCytomation) and 
the sections were counterstained 
in Mayer’s hematoxylin (Merck, 
Darmstadt, Germany).
4.5 Autoantibody studies 
by radioimmunoprecipitation 
assay (RIA)
4.5.1 Generation of antigens 
for RIA (III, IV, unpublished)
The antigens used in the RIA
 were  developed by PCR, subcloning 
and in vitro transcription-
translation. The primers used to 
produce recombinant intracellular 
parts of human densin, fi ltrin and 
nephrin are described in Table 
4. The inserts were cloned into a 
pGEM-4z circular plasmid vector 
(Promega) under T7 promoter 
sequence using specifi c restriction 
sites generated to the ends of 
the inserts. The plasmids were 
transformed into Escherichia coli 
Top-10 DH5-  (Invitrogen) cells 
using standard techniques. The 
purifi cation of the plasmids for in 
vitro transcription-translation (IVT) 
was performed with a plasmid 
purifi cation kit (HiSpeed Plasmid 
Maxi Kit, Qiagen). To verify that 
the cloning was successful and no 
mutations were present, PCR and 
sequencing were performed. 
In vitro transcription-translation 
with a TnT Coupled Reticulocyte 
Lysate System (Promega) and Redivue 
L-[35S]-methionine (Amersham 
Biosciences, Buckinghamshire, UK) was 
used to produce the 35S-methionine 
labeled recombinant proteins from 
the purifi ed plasmids. Unincorporated 
35S-methionine was removed by gel 
chromatography on a NAP-5 column 
(Amersham Biosciences, Uppsala, 
Sweden). The size of the translated 
proteins were characterised by sodium 
dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed 
by autoradiography of the dried 
gel on fi lm overnight.
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4.5.2 RIA  (III, IV, unpublished)
The labelled recombinant 
proteins produced by in vitro 
t r a n s c r i p t i o n - t r a n s l a t i o n 
were used as antigens in the 
radioimmunoprecipitation assay. 
Two or four µl of serum samples 
were incubated with 9000-15 
000 counts per minute (cpm) of 
the 35S-labeled densin, fi ltrin or 
nephrin recombinant protein in a 
total volume of 50 µl in TBST (Tris-
buffered saline with Tween-20, 50 
mmol/l Tris, 150 mmol/l NaCl (pH 
7.4), 0.1% Tween 20) for 7-18 hours. 
To isolate the immune complexes 
8 µl of protein A-sepharose 4B 
conjugate (Zymed Laboratories, 
San Francisco, California, USA) was 
added to a total volume of 50 µl of 
TBST. After incubation for one to 
two hours the samples were washed 
eight times with 140 µl of TBST. 
Scintillation cocktail (Optiphase 
‘SuperMix’ or Optiphase ‘HiSafe’ 
3, Wallac, Turku, Finland) was 
added and the activity measured 
with a liquid scintillation counter 
(1450 MicroBeta Trilux; Wallac). 
All incubations were performed at 
6°C on a shaker and each serum 
sample was measured at least as 
a duplicate. 
4.5.3 Densin, fi ltrin and nephrin 
autoantibody measurements (III, 
IV, unpublished)
For each of the antigen-specifi c 
RIAs, a dilution series of a serum 
pool or an antibody against a 
specifi c molecule were utilised 
in standardisation: a polyclonal 
antibody against densin (Apperson 
et al. 1996), a polyclonal antibody 
against nephrin (Ahola et al. 
2003) and a serum pool with high 
titre of FAA. These dilutions were 
given relative values of 1, 0.5, 
0.25, 0.125, 0.0625 and 0.03125, 
respectively. The standard curve 
of the dilution series on each plate 
was used to diminish the effect of 
interassay variation and to give 
the actual test samples a value in 
relative units (RU). The intra- and 
interassay coeffi cients of variation, 
mean levels of autoantibodies 
in healthy controls and cut-off 
limits for autoantibody positivity 
(mean+2.09 standard deviation, 
SD) for the University of Oulu 
patient material are presented in 
Table 7.
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NAA study (III)
 
DAA study (IV)
 
FAA study (IV)
 
Intra-assay 
coeffi cient
of variation
 
4.7
 
4.6
 
5.3
 
Interassay
coeffi cient
of variation
 
17.2
 
24.9
 
3.9
 
Mean level in
healthy controls
in RU (±SD)
 
0.066  (0.015)
 
0.1  (0.05)
 
0.018  (0.06)
 
Cut-off limit
for positivity,
RU
 
0.1
 
0.196
 
0.143
 
Table 7.  The main variables in the autoantibody studies. The cut-off limit 
for autoantibody positivity was determined by utilising mean autoantibody 
relative units (RU) in the healthy controls (mean +2.09 SD). NAA, nephrin 
autoantibodies; DAA, densin autoantibodies; FAA, fi ltrin autoantibodies.
4.5.4 Statistical analysis (III, IV)
Statistical analysis software 
(SPSS 12.0.1 for Windows; SPSS, 
Chicaco, IL, USA) was used to 
maintain a database of the 
patient and healthy control 
sample data, produce descriptive 
statistics of the groups and to 
test the correlation between the 
autoantibody levels (DAA, FAA, 
NAA) and other patient data 
parameters. Categorical variables 
were compared with chi-square 
statistics. Normally distributed 
continuous variables were tested 
with a two-tailed t-test for 
independent samples and analysis 
of variance. Nonparametric Mann-
Whitney U-test and Wilcoxon-
signed Rank test were applied 
to compare skewly distributed 
variables. Kaplan-Mayer survival 
curve was constructed for the 
time of diagnosis of diabetes 
to the time of diagnosis of 
microalbuminuria or proteinuria 
(III). Spearman’s non-parametric 
correlation analysis and Pearson 
correlation test were used to 
assess correlations. P-values <0.05 
were considered signifi cant.
4.6 Ethical issues (I, II, III, IV, 
unpublished)
The studies utilising human 
serum and tissue samples 
(Publications I, II, III, IV, unpublished) 
followed the principles of the 
Declaration of Helsinki. The study 
performed with the University 
of Oulu patient material was 
approved by the Ethics committee 
of the University of Oulu, and 
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the FinnDiane study protocol 
was approved by the local Ethics 
committee in each participating 
study centre. Written informed 
consent was obtained from each 
subject participating in the studies 
III, IV. The use of human tissues was 
approved by the Ethics Committee 
of the Helsinki University Central 
Hospital. The use of animal tissues 
(Publications I, III) was approved 
by the Ethics Committee of the 
University of Helsinki.
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5.1 Podocyte molecules in 
the pancreas (I, IV)
5.1.1 Pancreatic EST libraries (I)
To fi nd out which of the 
selected podocyte molecules 
(CD2AP, NEPH1, NEPH2, fi ltrin, 
FAT, synaptopodin, alpha-
actinin-4, podocin and densin) 
are expressed in the pancreas 
at the mRNA level, screening of 
pancreatic expressed sequence tag 
(EST) libraries was performed. The 
ESTs of all the studied molecules, 
except for podocin and densin, 
were found in the pancreatic 
expression libraries according to 
the Unigene database.
5.1.2 Expression at gene and 
protein level  (I, IV)
The expression of the selected 
podocyte molecules was studied 
at the mRNA level in the human 
pancreas (primers in Table 4). The 
mRNA expression of nephrin, 
CD2AP, FAT, alpha-actinin-4, 
NEPH1, fi ltrin, synaptopodin and 
densin were clearly detected. Only 
one podocin primer pair out of 
three (790-1052 base pairs, Table 
4) showed podocin-specifi c PCR 
signal in the pancreatic cDNA. 
5 Results
NEPH2 mRNA expression could 
not be detected in the human 
pancreas.
The expression of the podocyte 
molecules in the pancreas at 
the protein level was studied 
by immunoblotting. Protein 
bands of comparable size in the 
pancreas and the kidney lysates 
were detected for CD2AP, fi ltrin, 
alpha-actinin-4 and FAT. The 
podocin antibody recognised the 
major immunoreactive band of 
~35 kDa in the pancreas lysate 
instead of the band at ~44 kDa in 
kidney glomeruli. The presence of 
synaptopodin and NEPH1 in the 
pancreas could not be detected. 
5.1.3 Localisation (I, IV)
To elucidate the localisation 
of the podocyte proteins in 
the pancreas, pancreatic tissue 
sections were double-stained with 
antibodies to selected proteins 
and insulin or nephrin. Nephrin 
and insulin partially colocalised 
in the Langerhans islets as shown 
by an antibody against the whole 
intracellular part of nephrin. 
However, some staining with the 
antibody could be detected in 
other islet cell types as well.  FAT, 
53
fi ltrin, alpha-actinin-4 and densin 
positive staining was also found 
in the islets of Langerhans, mostly 
in the insulin producing beta cells. 
However, the colocalisation of FAT, 
fi ltrin and densin with insulin did 
not appear exclusive, suggesting 
that these proteins may also be 
expressed in other Langerhans 
islet cells than the beta cells. In 
addition, FAT and alpha-actinin-4 
antibodies showed some staining 
in the exocrine pancreas. Stainings 
with synaptopodin and NEPH1 
antibodies did not show a clear 
specifi c signal, which is consistent 
with the fi nding that neither of 
these proteins could be detected 
in the pancreas immunoblot. 
Podocin staining was not detected 
in the Langerhans islet cells but 
rather in the exocrine part of the 
pancreatic tissue. No staining with 
the CD2AP antibody was detected 
in the pancreas leaving the 
localisation of CD2AP undefi ned. 
As a summary, nephrin, FAT, 
fi ltrin, alpha-actinin-4 and densin 
expression was found in the 
Langerhans islet beta cells. 
5.2 Nephrin in human 
lymphoid tissues (II)
5.2.1 Gene expression 
Nephrin mRNA expression in 
the lymphoid tissues and cells 
was studied with RT-PCR and 
Real-time quantitative RT-PCR. 
Nephrin cDNA was detected in 
the human thymus, adenoid and 
tonsil tissues. In addition, nephrin 
was detected in the T lymphocytes 
(CD3+), monocytes (CD14+) and 
B lymphocytes (CD19+) isolated 
from human peripheral blood 
and monocyte-derived dendritic 
cells and macrophages after TNF-  
stimulation. The RT-PCR products 
from lymphoid tissues and cells 
were identical to the nephrin 
sequence in the kidney. The 
monocyte-derived macrophages, 
produced in the presence of 
GM-CSF after seven days of in 
vitro culture, showed no nephrin 
expression by conventional RT-
PCR.
Real-time quantitative RT-PCR 
was used to quantitate nephrin 
mRNA levels. Nephrin expression 
was about 34% in the tonsil, 
26% in the adenoid and 6% in 
the thymus of the expression 
level detected in the kidney. The 
T lymphocytes, B lymphocytes, 
monocytes and monocyte-derived 
dendritic cells and macrophages 
showed negligible nephrin mRNA 
expression and no nephrin was 
detected in the monocyte-derived 
macrophages.
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5.2.2 Protein expression 
Nephrin protein expression in 
the lymphoid tissues and cells was 
studied by immunoblotting. The 
nephrin antibody recognised a 185 
kDa and a smaller 165 kDa protein 
band from kidney cortex lysate as 
well as a protein of 165 kDa in 
human tonsil and adenoid lysates. 
The signal from the adenoid and 
tonsil could be blocked with 
pre-incubation of the antibody 
with the respective antigen 
used in immunisations, verifying 
specifi city of the antibody. No 
protein band with the nephrin 
antibody was detected in the 
immunoblot from the monocyte-
derived dendritic cells or 
monocyte-derived macrophages 
or in the lysates from human T 
lymphocytes (CD3+), monocytes 
(CD14+) or B lymphocytes (CD19+) 
separated from the peripheral 
blood.
5.2.3 Localisation 
Localisation of nephrin in the 
lymphoid tissues was studied by 
immunohistochemical staining. 
Staining of lymph node sections 
with the nephrin antibody showed 
staining of the germinal centres. 
Immunofl uorescence staining of 
frozen sections of human adenoid 
revealed membrane-type staining 
of cells in the B lymphocyte (CD19+) 
areas. No nephrin positive cells 
could be seen in the T lymphocyte 
region. The staining pattern was 
characteristic for interdigitating 
follicular cells, as verifi ed in the 
double-staining with nephrin 
and CD21 antibodies, a marker 
diagnostically used for detection 
of follicular dendritic cells. The 
specifi city of these stainings 
was confi rmed by blocking 
experiments.
5.3 Autoantibodies to 
nephrin, densin and fi ltrin in 
patients with type 1 diabetes 
(III, IV, unpublished)
The presence of autoanti-
bodies in the serum of type 1 diabetic 
patients against shared molecules 
between kidney glomerular 
podocytes and pancreatic beta 
cells (nephrin, fi ltrin, densin) 
were studied by individual 
radioimmunoprecipitation assays. 
5.3.1 Autoantibodies to 
nephrin (NAA) (III)
Altogether 43.9% of the 
patients with type 1 diabetes 
gave at least one sample positive 
for NAA, whereas none of the 
healthy control subjects showed 
positivity. At diagnosis, 24.2% 
patients tested positive for NAA 
and the respective proportions 
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at 2, 5 and 10 years were 23.0%, 
13.8% and 18.2%. Only four 
patients (6.1%) tested positive in 
all measured samples. The levels 
of NAA fl uctuated considerably 
over the 10-year measurement 
period.
5.3.2 Autoantibodies to densin 
(DAA) (IV)
Altogether 33.3% of the 
patients gave at least one sample 
positive for DAA, whereas only 
2.2% of the healthy control 
subjects showed positivity 
(p<0.001). At diagnosis, 22.7% 
patients tested positive for DAA. 
The respective proportions at 2, 
5 and 10 years were 8.2%, 13.8% 
and 9.1%. Of the 22 DAA positive 
patients, 14 had detectable densin 
autoantibodies at one of the time 
points, eight at two or three time 
points and none at all four time 
points, respectively. Similar to the 
established diabetes-associated 
autoantibodies (ICA, GADA, IA-
2A), DAA positivity was typically 
detected already at diagnosis in 
most (68.2%) DAA positive cases. 
Furthermore, the DAA titres 
were the highest at diagnosis 
and decreased signifi cantly 
already by 2 years of follow-up 
(p<0.001).
5.3.3 Autoantibodies to fi ltrin 
(FAA) (IV)
Altogether 10.6% of the 
patients had at least one sample 
positive for FAA, whereas only 
2.6% of the healthy control 
subjects showed FAA positivity 
(p=0.049). At diagnosis, FAA 
were detected in 3.0% of the 
patients and the proportions 
at 2, 5 and 10 years were 4.9%, 
5.2% and 6.8%, respectively. 
Of the seven positive patients, 
four had detectable FAA at 
one of the time points, three 
at two or three time points and 
none at all four time points. 
In contrast to DAA, FAA could 
appear at any time point during 
the 10-year observation period 
and FAA titres did not change 
signifi cantly during the follow-
up (p=0.281).
5.3.4 Clinical and genetic 
profi le of the patients (III, IV)
The clinical data of the 
University of Oulu patient 
material at diagnosis was 
categorised by the presence 
or absence of NAA, DAA or 
FAA. The examination did not 
show signifi cant differences in 
addition to the fi nding that DAA 
positivity was seen considerably 
less frequently among males 
than among females. 27.2% of 
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the patients were diagnosed 
with diabetic retinopathy 
during the follow-up period 
but no association was detected 
between the presence of NAA 
and the development of diabetic 
retinopathy.
The association between 
NAA, DAA and FAA and 
different HLA DR genotypes 
was also investigated. No 
signifi cant association could be 
seen between DAA or FAA and 
various HLA DR combinations. 
However, the NAA and FAA 
positive patients always carried a 
HLA DR3 and/or HLA DR4 allele.
5.3.5 Immunological profi le of 
the patients (III, IV)
The prevalence of NAA, 
DAA, FAA, ICA, GADA, IA-2A at 
different time points during the 
10-year follow-up are presented 
in Figure 4. The prevalences of IA-
2A and GADA closely followed the 
prevalence of ICA. The proportion 
of ICA (p=0.004), GADA (p=0.024) 
and IA-2A-positive patients 
(p<0.001) decreased from the 
time of diagnosis to the end of 
the follow up, and a similar trend 
was observed for DAA (p=0.010) 
but not for FAA (p=0.13). 
Furthermore, NAA titers did not 
correlate with ICA titers during 
the ten year follow-up. 
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Figure 4. Prevalence of the different autoantibody specifi cities during the ten 
year follow-up. The fi gure is modifi ed from Publication IV by adding the NAA 
prevalence reported in Publication III.
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The possible association of 
DAA and FAA positivity with 
the positivity for the diabetes-
associated autoantibodies at 
different time points was also 
assessed. An association could 
be detected between DAA and 
GADA prevalence at diagnosis 
(p=0.023) and at 10 years (p=0.045). 
Furthermore, the DAA positive 
patients had higher titers of GADA 
(p=0.001) and ICA (p=0.051) at 
diagnosis compared to the DAA 
negative patients. On the contrary, 
no association was seen between 
FAA and the diabetes-associated 
autoantibodies. The NAA, DAA or 
FAA were never detected alone, 
but rather they were always 
observed in patients in conjunction 
with other diabetes-associated 
autoantibodies.
In summary, NAA (24.2%), DAA 
(22.7%) and FAA (3.0%)  have a 
low prevalence when comparing to 
either ICA (80.0%), GADA (61.5%) 
or IA-2A (80.0%) at diagnosis.
5.3.6 NAA, DAA and FAA in 
diabetic nephropathy 
(III, IV, unpublished)
The association between the 
novel autoantibodies (NAA, DAA, 
FAA) with diabetic nephropathy 
was studied using two separate 
patient materials; the University 
of Oulu patient material and the 
Finnish Diabetic Nephropathy 
(FinnDiane) study patient material. 
The patients in the FinnDiane 
material had had longer duration 
of diabetes and more symptoms of 
diabetic nephropathy compared 
to the University of Oulu patient 
material, thus the material was 
valuable in elucidating further the 
persistence of the autoantibodies 
and their association to diabetic 
kidney disease.
In the University of Oulu 
patient material, only a minority 
of the patients had developed 
signs of diabetic kidney disease. 
Among the 66 patients in this 
study, 14 (21.2%) had developed 
microalbuminuria during the 
total observation period of 
17 to 19 years, and three of 
them (4.5%) had progressed to 
proteinuria. The mean duration 
of diabetes at the manifestation 
of microalbuminuria and 
proteinuria were 9.5 and 12.0 
years, respectively. The time 
from diagnosis of diabetes to 
manifestation of renal injury 
varied considerably between the 
patients. Among the 14 patients 
with signs of renal injury, four 
(28.6%) tested positive for NAA 
at least at one of the time points. 
The corresponding numbers 
were four (28.6%) for DAA and 
two (14.3%) for FAA. In patients 
with NAA the mean duration 
of diabetes at manifestation of 
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microalbuminuria was 7.7 years 
whereas the patients free of 
NAA had a later manifestation of 
microalbuminuria at a mean of 
10.1 years. However, this fi nding 
was statistically insignifi cant 
(p=0.42). All the three patients 
with proteinuria had DAA at one 
of the time points. No association 
could be detected between the FAA 
levels and manifestation of renal 
injury. In conclusion, no signifi cant 
association of NAA, DAA or FAA to 
the manifestation or development 
of diabetic nephropathy was 
detected in the University of Oulu 
patient material.
A subsequent study was 
performed to investigate further the 
possible association of the expression 
of these novel autoantibodies to 
diabetic nephropathy. The type 1 
diabetes patient material from the 
FinnDiane study was utilised for 
this purpose. The mean duration of 
diabetes in these patients was 22.6 
years compared to the maximum of 
19 years in the University of Oulu 
material. None of the FinnDiane 
serum samples, being either normo-
, micro- or macroalbuminuric (thus 
being in different stages in the 
development of diabetic kidney 
disease), showed specifi c binding 
against nephrin, densin or fi ltrin 
autoantigens (unpublished results). 
The combined results from the 
University of Oulu and FinnDiane 
patient materials suggests that 
these novel autoantibodies are 
detected in a subset of patients 
with type 1 diabetes during the 
fi rst ten years of clinical diabetes 
but are no longer detected in long-
lasting  diabetes.
5.3.7 Staining pattern of 
patient and healthy subjects sera 
(III)
It has been reported that 
autoantibodies against nephrin 
can be detected in CNF patient 
sera after kidney transplantation, 
and that a subset of CNF patient 
sera stain kidney sections in a 
glomerulus-like fashion in indirect 
immunofl uorescence (Wang et al. 
2001; Patrakka et al. 2002). Based on 
these fi ndings we performed indirect 
immunofl uorescence staining with 
diabetic patient sera to investigate 
if a similar phenomenon is detected. 
Immunofl uorescence staining for 
rat kidney cortex sections was 
performed with the three diabetic 
serum samples with highest titers 
of NAA and three healthy control 
samples negative for NAA. An 
epithelial-like glomerular staining 
typical for nephrin was detected 
with two out of three of the highest 
serum samples and one of them 
showed no staining. Stainings 
with negative healthy control sera 
and secondary antibodies alone 
showed no specifi c reactivity.
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6.1 Podocyte proteins in 
the beta cells of the pancreas 
(I, IV)
In Publication I and IV, the 
podocyte molecules fi ltrin, FAT, 
alpha-actinin-4 and densin were 
found to be expressed in the 
pancreas, preferentially in the 
insulin-producing beta cells of 
the Langerhans islets. In addition, 
the expression of nephrin in the 
human pancreatic islet beta cells 
was confi rmed, contradicting 
a recent report by Kuusniemi 
and colleagues (Kuusniemi et 
al. 2004). They studied nephrin 
expression at the mRNA and 
protein level in many extrarenal 
tissues of human and pig but they 
did not detect nephrin protein in 
any other tissue than the kidney. 
In the immunofl uorescence 
studies they used an antibody 
against the whole intracellular 
part of nephrin as we did in 
study I. The contradicting results 
could be due to differencies 
in tissue collection protocols 
since it is known that pancreatic 
tissue requires extremely rapid 
tissue preservation to prevent 
any protein degradation. There 
could also be some differencies 
in our staining protocols which 
could affect the results. Zanone 
6 Discussion
and colleagues have also 
studied nephrin expression in 
the pancreas but they suggest 
nephrin to be solely expressed in 
the endothelial cells of pancreatic 
islet microcirculation (Zanone et 
al. 2005). Based on our studies, 
the partially similar expression of 
these molecules in the podocytes 
and the beta cells suggests 
similarities in the molecular 
composition between these two 
cell types.
6.1.1 Structure of the 
hypothetical protein complex
Adherens junctions, the main 
components which are cadherins, 
regulate the adhesive properties 
of the beta cells (Rouiller et al. 
1991). Cadherins are a family 
of ubiquitously expressed 
transmembrane cell adhesion 
molecules which mediate the 
homophilic cell-cell adhesion 
between neighbouring cells 
(Takeichi et al. 1988). Cadherins 
bind with their cytoplasmic 
tails to members of the catenin 
family, which link the cadherins 
to the cell cytoskeleton (Ozawa 
et al. 1989). The main cadherin 
of the pancreatic islet cells, the E-
cadherin, has been shown to be 
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crucial for the proper organisation 
of the endocrine pancreas during 
development (Rouiller et al. 1991; 
Dahl et al. 1996). 
In the present study, it was 
hypothesised on the basis of our 
novel fi ndings of the podocyte 
proteins (nephrin, densin, fi ltrin, 
FAT and alpha-actinin-4) in the 
pancreatic beta cells, and the 
previous knowledge of the role of 
these molecules in other tissues, 
that these molecules participate 
in adherens junction-type cell-
cell contacts between the beta 
cells comparable to those in the 
podocytes (Reiser et al. 2000).
There are many studies 
suggesting an interaction 
between these novel beta cell 
molecules and adherens junction 
molecules in tissues other than 
pancreas. An interaction between 
densin and a cadherin-family 
member has been shown in 
neurons and podocytes, specifi cally 
an interaction with N-cadherin in 
the neuron (Izawa et al. 2002) and 
with P-cadherin in the podocyte 
(Heikkilä et al, unpublished 
results). Since densin binds to both 
N- and P-cadherin, it probably can 
bind to the E-cadherin suggesting 
a similar interaction between an 
established adherens junction 
molecule and densin in the 
beta cells. Interestingly, nephrin 
has been found from the same 
protein complex with densin and 
P-cadherin in the glomerulus 
(Heikkilä et al, unpublished 
results), suggesting that nephrin 
could be associated with the 
same adherens junction-like 
protein complex. Furthermore, 
densin has been shown to directly 
interact with the actin bundling 
protein alpha-actinin-4 in the 
brain (Walikonis et al. 2001). 
The extracellular parts of NEPH1 
(Barletta et al. 2003) and NEPH2 
(Gerke et al. 2005) have been 
shown to interact with nephrin 
in the podocytes, and based on 
the homology, fi ltrin suggestively 
interacts as well. FAT, the large 
protocadherin found in the beta 
cells, has been suggested to be 
able to bind to catenins (Ponassi 
et al. 1999). Thus, the hypothetical 
protein complex formed by E-
cadherin, densin, nephrin, fi ltrin 
and FAT could be linked to the 
beta cell cytoskeleton via both 
alpha-actinin-4 and/or catenins. 
Furthermore, nephrin could 
possibly act in a homophilic 
fashion to strengthen the cell-
cell contact formed by E-cadherin 
between neighbouring cells.
6.1.2 Function of the 
hypothetical protein complex
What could be the implication 
of this suggested adherens 
junction-like cell-cell contact in 
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the beta cell? E-cadherin mediated 
cell adhesion between the islet 
cells has been shown to be crucial 
for insulin secretion (Cirulli et al. 
1993; Yamagata et al. 2002), thus 
the hypothetical protein complex 
might have an indirect role in 
insulin secretion by maintaining 
the appropriate islet structure. 
Signaling processes may play a 
role in this process since many of 
these novel beta cell molecules 
(Huber et al. 2005) have been 
shown to have signaling function 
in addition to the signaling 
function shown for the cadherin-
catenin complex (Wheelock et al. 
2003). Interestingly, nephrin has 
been suggested to have a crucial 
role in insulin responsiveness in 
the novel insulin target tissue, the 
podocytes (Coward et al. 2005a; 
Coward et al. 2005b). There 
nephrin appears to be needed for 
the proper translocation of insulin 
independent glucose transporter 
molecule GLUT1 and insulin 
dependent glucose transporter 
GLUT4 to the plasma membrane 
(Coward et al. 2005a). GLUT2 in 
an insulin independent glucose 
transporter found from the beta 
cells, thus it can be hypothesised 
that nephrin would be needed for 
GLUT2 translocation in these cells. 
Hence nephrin and its associated 
protein complex may have an 
active role in glucose transporter 
translocation in insulin producing 
beta cells as well as in novel insulin 
sensitive cells, the podocytes, in 
addition to a suggested structural 
role in adherens-like junctions. 
Nephrin, however, does not 
appear to be crucial for the insulin 
secretion of the beta cells since 
no defi ciency in glucose tolerance 
has been detected in CNF patients 
and CNF patients do not appear 
to be more prone to develop 
diabetes (Kuusniemi et al. 2004).
As a conclusion, nephrin 
could take part in GLUT2 
translocation in pancreatic beta 
cells, and furthermore, it can be 
hypothesised that there could be 
a novel adherens junction–like 
cell-cell contact, formed by E-
cadherin, nephrin, fi ltrin, densin 
and FAT in the beta cells. This 
junction could participate in the 
establishment and maintenance of 
the islet architecture and this way 
indirectly affect the ability of the 
beta cells to secrete insulin. Alpha-
actinin-4 and/or catenins could link 
this whole complex to the beta 
cell cytoskeleton. This hypothesis 
could be tested by studying 
pancreas-specifi c interactions by 
co-immunoprecipitations and 
the exact localisation of these 
molecules in the pancreas by 
immunoelectronmicroscopy. 
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6.2 Nephrin in human 
lymphoid tissues (II)
In study II, nephrin expression 
was found in the lymphoid 
tissues, specifi cally in the germinal 
centres of the lymphoid follicles 
in the adenoids and lymph nodes. 
Nephrin was detected as a 165-kDa 
protein corresponding to the size 
of nephrin found in the pancreas 
(Palmen et al. 2001). This suggests 
different posttranslational 
modifi cation, especially 
glycosylation, in the lymphoid 
tissues and pancreas compared 
to glomerular podocytes where 
the size is 185 kDa (Holzman 
et al. 1999; Ruotsalainen et al. 
1999). Colocalisation with the 
CD21 antibody suggests nephrin 
expression specifi cally in the 
follicular dendritic cells (FDC) 
of the germinal centres. Since 
nephrin has a central structural 
role in the interpodocyte slit 
diaphragm, it may comparably 
participate in the maintenance of 
the lymphoid follicle structure in 
the lymphoid tissues.
In the lymphoid follicle 
germinal centre, the antigen-
activated B cells rapidly expand 
and differentiate when they 
come into contact with FDCs, 
generating plasma cells and 
memory B cells. These cells have 
the capacity to produce antigen-
specifi c antibodies. The FDCs 
maintain the framework of the 
lymphoid follicle and offer the B 
lymphocytes a stable network for 
proliferation and differentiation. 
The characteristic feature of 
FDCs is that they do not process 
and present antigens in HLA II 
molecules but rather present 
intact antigen-antibody complexes 
on their surface. The antigen-
antibody complexes are held on 
the cell surface by Fc receptors or 
by complement receptors such as 
CD21. The contact between the 
germinal centre B cells and FDCs 
is crucial, since only those B cells 
that bind to immune complexes 
on FDCs surface can survive; the 
B cells which can not bind to the 
immune complexes are removed 
by apoptosis. If the regulation of 
B-cell apoptosis and elimination 
of self-reactive B cells is impaired, 
it results in autoimmune diseases 
(Park et al. 2005). 
Germinal centre FDCs and 
glomerular podocytes appear to 
have some structural similarity 
since both of them have 
long extending cytoplasmic 
processes and cell-cell junctions 
between these processes from 
neighbouring cells. In addition 
to the frequent desmosome-like 
junctions between the processes 
(Schafer et al. 1996), adherens 
junctions with “classical“ 
cadherins and beta-catenin have 
been suggested to exist in the 
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human FDCs (Muller et al. 2000). 
Furthermore, the formation of 
adherens junctions appears to be 
a prerequisite for the formation 
of desmosomes (Huber 2003). 
Since nephrin has been associated 
with adherens junction-like 
cadherin-catenin complex in the 
glomerulus (Lehtonen et al. 2004), 
it could have a similar association 
in the FDCs. Thus, nephrin could 
in a comparable manner to its 
function as a structural adhesion 
molecule in the slit diaphragm, 
act in the germinal centres as a 
adherens junction molecule and 
support the FDC network. In CNF 
patients (who lack functional 
nephrin), however, no dysfunction 
in B cell maturation or in antibody 
production has been reported, 
thus it can not be suggested that 
nephrin would be essential for 
the function of FDCs. Multiple 
infections are seen in patients 
with CNF but they have been 
suggested to be a consequence 
of antibody loss by proteinuria 
(Huttunen 1976; Hamed et al. 
2001) rather than a defect in 
antibody production. 
6.3 Novel autoantibodies in 
patients with type 1 diabetes 
(III, IV)
In studies III and IV, 
autoantibodies against novel 
beta cell molecules, nephrin, 
densin and fi ltrin, were found in 
a subset of patients with type 1 
diabetes followed from the time 
of diabetes diagnosis for ten 
years. These autoantibody studies 
were based on the discovery of 
the novel beta cell molecules 
in studies I and IV, as well as on 
a report of nephrin expression 
in the pancreas by Palmen and 
colleagues (Palmen et al. 2001). 
Nephrin, densin and fi ltrin were 
selected in these autoantibody 
studies since they appear to have 
a very restricted tissue expression 
pattern, mainly in the kidney, 
the brain and the pancreas, as 
well as restricted expression in 
the pancreas itself, mainly in 
the beta cells of the Langerhans 
islets. For the autoantibody 
screenings, intracellular parts 
of these molecules were chosen 
as antigens, since in healthy 
individuals they are assumed to 
be protected in the cytoplasm, but 
during the immune destruction of 
the beta cells in type 1 diabetes 
these antigens can be released 
from the cytoplasm and induce 
a humoral immune response. 
Furthermore, since GAD and IA-2 
both are intacellular molecules, it 
gave further justifi cation for the 
selection of intracellular parts 
of nephrin, densin and fi ltrin 
as antigens. Humoral immune 
responses to various beta cell 
autoantigens, such as insulin, IA-
2 and GAD have been shown to 
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associate with the early stages of 
diabetes.
GADA and/or IA-2A are 
present in more than 90% of 
the cases with recent onset type 
1 diabetes (Savola et al. 1998a), 
and they are used as markers 
for type 1 diabetes. Compared 
to the established diabetes-
associated autoantibodies (IAA, 
IA-2A, GADA and ICA), nephrin 
(NAA), densin (DAA) and fi ltrin 
autoantibodies (FAA) appeared to 
have a low prevalence at the time 
of diagnosis of clinical diabetes. 
The prevalence of NAA and DAA 
declined over time comparable to 
the prevalence of ICA, IA-2A and 
GADA, suggesting that NAA and 
DAA are also generated during 
the early autoimmune process 
leading to type 1 diabetes. 
DAA especially were typically 
detected already at the time of 
diagnosis in the diabetic patients 
and declined sharply thereafter. 
FAA was an exception to NAA 
and DAA since its prevalence 
did not decrease during the 
ten-year follow-up period and, 
furthermore, FAA could appear 
at any time point during the 
follow-up. This could, however, 
result from the fact that FAA 
were apparently expressed in 
lower levels than the other novel 
autoantibodies in the patient 
sera. Such low levels can easily 
be interpreted as a negative 
fi nding, especially since we chose 
a relatively high cut-off limit for 
positivity to avoid false-positive 
interpretations. 
6.3.1 Mechanisms of 
autoantibody formation
At least two mechanisms 
could be responsible for the 
formation of these novel 
autoantibodies during the 
autoimmune process of type 1 
diabetes: epitope spreading and 
loss of self-tolerance to specifi c 
molecules. It has been suggested 
that in those individuals who 
develop type 1 diabetes, islet 
cell autoimmunity starts as a 
non-pathogenic Th2 (T helper 
2) response of the T helper cells, 
but develops into a pathogenic 
Th1 (T helper 1) response. The 
Th1 response is associated with 
epitope spreading (Katz et al. 
1995; Petersen et al. 1999; Tuohy 
et al. 1999). Epitope spreading is 
a mechanism where the original 
autoimmune reaction against 
one epitope in one molecule 
is extended to other epitopes. 
Epitope spreading in detected 
within one molecule, eg. for GAD 
(Bonifacio et al. 2000; Sohnlein et 
al. 2000; Hoppu et al. 2004)  and 
IA-2 (Naserke et al. 1998), but 
also between different molecules 
(Naserke et al. 1998). Thus, the 
development of autoantibodies 
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against nephrin, densin and 
fi ltrin in diabetic patients could 
be due to intermolecular epitope 
spreading from the original 
priming antigens in insulin, IA-2 
and/or GAD to nephrin, densin 
and fi ltrin antigens.
Another possible explanation 
for the formation of 
autoantibodies againt nephrin, 
densin and fi ltrin could be the 
impairment in the development 
of self-tolerance to these 
molecules. The thymus has an 
ability to express small amounts 
of tissue-restricted antigens to 
be recognised by the developing 
T cells, which results in tolerance 
of the immune system to these 
antigens; if this is impaired it 
can result in an autoimmune 
reaction against these molecules 
(Derbinski et al. 2005). Impaired 
expression of insulin by the 
thymus has been suggested to be 
a factor in the development of 
autoimmunity in type 1 diabetes 
(Bennett et al. 1995; Pugliese et 
al. 1997; Vafi adis et al. 1997). An 
impaired expression of nephrin, 
densin and fi ltrin in the thymus 
could thus potentially explain 
the autoimmune reaction against 
these molecules. Interestingly, 
nephrin expression was detected 
in the thymus at the mRNA level 
in study II, which could represent 
the thymic expression needed 
for nephrin tolerance. One 
possibility to test this hypothesis 
could be to determine if nephrin 
expression is impaired in the 
thymus of patients with type 1 
diabetes.
In summary, NAA, DAA 
and FAA were present in the 
serum of a subset of patients 
with type 1 diabetes, and they 
are suggestively a part of the 
common humoral autoimmune 
response seen in type 1 diabetes. 
This view is further supported 
by the fi nding that NAA, DAA 
and FAA were always detected 
in conjunction with the 
established diabetes-associated 
autoantibodies. 
6.4 Novel autoantibodies 
in diabetic nephropathy 
(III, IV, unpublished)
In studies III and IV and in the 
following unpublished study, the 
possible association of NAA, DAA 
and FAA with the pathogenesis of 
DN was explored. The hypothesis 
that these novel circulating 
autoantibodies could be 
associated with the pathogenesis 
of DN was based on the following 
fi ndings: a signifi cant proportion 
of patients with CNF treated with 
renal transplants had circulating 
antibodies to nephrin (Wang et 
al. 2001; Patrakka et al. 2002) 
and an injection of monoclonal 
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nephrin antibody to rats resulted 
in massive proteinuria (Orikasa et 
al. 1988; Topham et al. 1999). It 
was also shown that the nephrin 
antibodies can reach the podocytes 
and bind to them (Orikasa et al. 
1988). Interestingly, the staining 
of rat kidney sections with a type 
1 diabetic patient sera with high 
nephrin autoantibody titer (study 
III) showed epithelial-like staining 
in the glomerulus. However, since 
no blocking experiments with 
nephrin antigen were performed, 
it cannot be argued that the 
staining was nephrin-specifi c. 
In the studies performed with 
the University of Oulu patient 
material (studies III and IV), with 
a ten-year follow-up from the 
diagnosis of type 1 diabetes, NAA, 
DAA and FAA were found in a 
subset of patients with signs of 
DN, but no association was found 
between the autoantibodies 
and the development of DN; 
the patients developing kidney 
complications and those 
remaining unaffected had a 
similar prevalence of NAA, DAA 
and FAA. The University of Oulu 
patient material was not optimal 
in exploring the association 
of these autoantibodies to DN 
since the diabetes duration was 
only maximum for 10 years and 
only 14 patients out of a total 
of 66 patients had any signs of 
the kidney complication. Thus 
the study cohort may have been 
too small to assess the possibility 
that circulating antibodies 
induced by nephrin, densin and 
fi ltrin in the pancreas could end 
up in the kidney glomerulus 
and recognise the respective 
epitopes in the kidney. However, 
when the presence of these 
autoantibodies was studied in 
patients with longer duration 
of diabetes (average 22.6 
years, unpublished study) and 
established symptoms of DN, no 
autoantibodies were detected. 
This fi nding strengthens the 
view that NAA, DAA and FAA 
are associated with the early 
stages of type 1 diabetes rather 
than with the later stages and 
late diabetic complications such 
as DN.
6.5 Conclusions and future 
prospects
In this thesis work, novel 
expression sites of podocyte 
molecules were shown, specifi cally 
densin, fi ltrin, FAT and alpha-
actinin-4 in the pancreatic beta 
cells and nephrin in the lymphoid 
follicle germinal centres. The role 
of these molecules at these novel 
expression sites is proposed to be 
mostly a structural one, behaving 
as components of the adherens 
junction-like cell-cell contacts. 
Interestingly, all these molecules 
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appear to have a comparable 
tissue expression pattern since 
nephrin, densin, fi ltrin, FAT as 
well as alpha-actinin-4 have all 
been reported to be expressed in 
the renal podocytes, pancreatic 
beta cells and neurons of the 
brain. Further studies are needed 
to decipher the exact localisation 
and role of these molecules, and 
the structural and functional 
similarities of these three tissue 
types. 
Autoantibodies against 
the novel beta cell molecules 
nephrin, densin and fi ltrin were 
found in a subset of patients 
with type 1 diabetes. However, 
no association could be shown 
between these autoantibodies 
and the development of diabetic 
nephropathy. It would be 
interesting to fi nd out if these 
novel autoantibodies can be 
found in patients with LADA (the 
latent autoimmune diabetes is 
adults) and if they would be useful 
in the prediction or classifi cation 
of this form of autoimmune 
diabetes. This would be especially 
interesting in the context of of 
densin autoantibodies since they 
were associated with GADA titers 
and GADA prevalence in the ten 
year follow-up material.
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